antaranusa.com | berita nusantara internasional

Univar Solutions Expands Plant-based Ingredient Portfolio Through Strategic Collaboration with Roquette in North America

Thu, 05 Nov 2026 07:23:00 +0700

New collaboration enhances customer access to plant proteins, fibers, and cellulosics, driving innovation in health and nutrition markets

DOWNERS GROVE, Ill., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Univar Solutions LLC ("Univar Solutions" or "the Company"), a leading global solutions provider to users of specialty and essential ingredients, announced a new distribution relationship between its Foodology by Univar Solutions business and Roquette, a global leader in plant-based ingredients.

The agreement includes an expanded cellulosics portfolio as well as NUTRALYS plant proteins and NUTRIOSE soluble fibers, strengthening Foodology by Univar Solutions' plant-based offerings for customers in the United States and Canada.

"Together with Roquette, a global pioneer in plant-based ingredients, we're delivering on our promise of bringing innovative, sustainable solutions to our customers," said Aaron Lee, senior vice president of Health & Nutrition for Univar Solutions. "By expanding our collaboration beyond cellulosics to include plant proteins and fibers in North America, we're aligning Roquette's leadership in food innovation with our unmatched supply chain and market intelligence to help shape the future of nutrition. Through this collaboration, we're putting Feeding Healthy Tomorrows into action, one project at a time."

NUTRALYS pea protein is a line of versatile plant-based protein ingredients derived from non-GMO yellow peas using Roquette's patented water-based process. NUTRIOSE soluble fiber, sourced from non-GMO wheat or corn, delivers a neutral taste that preserves original flavor, along with clinically proven digestive tolerance and exceptional process stability. The cellulosics portfolio includes METHOCEL, WELLENCE, ETHOCEL, TABULOSE, and MICROCEL, enabling customers to deliver texture, stability, processing performance, and consumer experiences across a wide range of food applications. With over 90 years of expertise, Roquette stands at the forefront of food and nutrition innovation, pioneering healthier, more sustainable, plant-based food solutions.

"We are pleased to expand our collaboration with Univar Solutions beyond cellulosics to include plant proteins and fibers," said Gaetan Fauvarque, Head of Global Distribution Management for Roquette's Nutrition and Bio-industry Business Unit. "This expanded relationship will make more of our products available to customers in North America. Together, we can build on our respective strengths to bring innovative plant-based solutions to more customers and better respond to evolving needs across the food and nutrition industry."

The portfolio will support a range of food and beverage applications including protein beverages, fortified snacks, plant-based diets, baked goods, and meat alternatives - aligning with key market trends such as protein fortification, plant-based diets, weight management therapeutics, and increased fiber intake. With a strong focus on nutraceuticals and sports nutrition, the portfolio's novel ingredients also help consumers adopt and maintain healthier lifestyles.

Learn how Foodology by Univar Solutions helps brands stay ahead of evolving consumer preferences by delivering high-quality ingredients and innovative recipes.

About Univar Solutions

Univar Solutions is a leading global specialty chemical and ingredient distributor representing a premier portfolio from the world's leading producers. With one of the industry's largest private transportation fleets and technical sales force, unparalleled logistics know-how, deep market and regulatory knowledge, formulation and recipe development, and leading digital tools, the Company is well-positioned to offer tailored solutions and value-added services to a wide range of markets, industries, and applications. While fulfilling its purpose to help keep communities healthy, fed, clean, and safe, Univar Solutions is committed to helping customers and suppliers innovate and focus on Growing Together. Learn more at univarsolutions.com.

About Roquette

Roquette is a global leader in sustainable plant-based solutions and driving innovations that are shaping the future of nutrition, health, and the bioindustry. The company harnesses natural resources such as wheat, corn, seaweed, and cellulose to craft high-performance ingredients used in everyday foods, oral medications, advanced biopharmaceuticals, and a range of bio-based products. A family-owned company with over 90 years of expertise and 11,000 employees, Roquette serves clients in over 150 countries and is committed to creating lasting value for customers, patients, consumers, and society. Together, we turn the potential of nature into the essentials of life. Discover more about Roquette here.

Forward-Looking Statements and Information

This communication contains "forward-looking statements" under applicable law regarding financial and operating items relating to the Company's business. Forward-looking statements generally can be identified by words such as "believes," "expects," "may," "will," "should," "could," "seeks," "intends," "plans," "estimates," "anticipates" or other comparable terms. All forward-looking statements made in this communication are qualified by this cautionary language.

Although the forward-looking statements are based on what management believes to be reasonable assumptions, we caution you that the forward-looking information presented in this communication is not a guarantee of future events or results, and that actual events or results may differ materially from those made in or suggested by the forward-looking information contained in this communication.

For additional information regarding factors that could affect the Company, please see the Company's most recent annual report and other financial reports, including the information set forth under the caption "Risk Factors." Any forward-looking statements represent the Company's views only as of the date of this communication and should not be relied upon as representing the Company's views as of any subsequent date, and the Company undertakes no obligation, other than as may be required by law, to update any forward-looking statement.

28-Year Caterer Lavish Dine Keeps Nyonya Traditions Relevant Amid Singapore's Heritage Push

Thu, 05 Nov 2026 07:17:00 +0700

Source: Lavish Dine Catering Pte Ltd

As Singapore steps up heritage preservation, 28-year Halal-certified caterer Lavish Dine puts Peranakan cuisine centre stage with its SG61 Island Collection, bringing Tok Panjang and hawker-rooted flavours to weddings, corporate events and community celebrations to keep culinary traditions alive.

SINGAPORE - Media OutReach Newswire - 4 November 2026 - Singapore's inaugural SG Heritage Business Scheme has renewed attention on the survival of long-running local trades. Against this preservation push, Lavish Dine Catering shows how catering can keep labour-intensive Nyonya cooking commercially active by serving it at scale across contemporary celebrations.

Keeping Nyonya Craft Alive

Between 2015 and 2025, Singapore's F&B sector grew 42% amid openings and closures, intensifying pressure on labour-intensive cuisines. Amid this churn, Lavish Dine scales Peranakan cooking for events, retaining hand-ground rempah and slow-cooking techniques across its catering, while the SG61 Island Collection extends that approach to preserve local food heritage through a catering experience.

Taking Peranakan Heritage Beyond the Restaurant

Singapore's F&B churn has also pushed heritage preservation higher on the agenda. In February 2026, the Ministry of Trade and Industry reaffirmed efforts to preserve local heritage in F&B, including support for established operators and curated food experiences. For Lavish, that preservation happens through continued use, keeping Peranakan cooking on event menus and in front of new audiences.

"Peranakan cuisine holds a special place in our hearts because its recipes carry so much history and meaning. For nearly three decades, we have had the privilege of bringing these flavours to events across Singapore. To us, the best way to honour this heritage is to keep sharing it. Every catered occasion is a chance to introduce these dishes and the stories behind them to new generations and communities, so they can continue to live on," said Richie Ling, Director, Lavish Dine Catering.

Lavish's SG61 Island Collection exemplified this, tracing Singapore's culinary story from Tok Panjang traditions to hawker classics. Its Peranakan catering menus remain available for events across Singapore.

About Lavish Dine Catering Pte Ltd:

Established in 1998, Lavish Dine Catering Pte Ltd provides premium catering for corporate events, weddings, private celebrations and other occasions in Singapore. Its work combines bespoke menus, themed presentation and interactive dining experiences. Guided by its "Redefining Catering" philosophy, Lavish explores culinary innovation and sustainable practices.

For more information, please visit: https://www.lavish.com.sg/

The issuer is solely responsible for the content of this announcement.

Hashtags: #LavishDine

https://www.lavish.com.sg/

https://www.linkedin.com/company/lavishdinesg/

https://www.facebook.com/lavishdinesg/

https://www.instagram.com/lavishdine

Boehringer Ingelheim and SBP Group enter partnership to advance next-generation cancer therapies

Thu, 05 Nov 2026 07:12:00 +0700

*Partnership provides opportunities to further expand Boehringer Ingelheim's portfolio of antibody-drug conjugates (ADCs) and T-cell engagers (TcEs)

*Agreement reinforces Boehringer Ingelheim's long-term commitment to China's innovation ecosystem and validates SBP Group's innovative R&D capabilities

*SBP Group to receive US$358 million in upfront and near-term payments and is eligible for potential option-exercise, development, regulatory and commercial milestone payments of US$7 billion, plus up to double-digit royalties on future product sales

Ingelheim, Germany, and Hong Kong/China, 4 November 2026 - Boehringer Ingelheim, headquartered in Germany, and Sino Biopharmaceutical Limited (01177.HK; together with its subsidiaries, "SBP Group") today announced a strategic multi-program option and license agreement to advance potential next-generation cancer treatments based on antibody-drug conjugate (ADC) and T-cell engager (TcE) technologies. Deepening the companies' existing partnership in oncology, the new agreement combines SBP Group's innovative platforms and early-development capabilities with Boehringer Ingelheim's global oncology expertise to advance new treatment approaches for patients worldwide.

Cancer remains one of the world's greatest health challenges, with approximately 20.6 million new cases and close to 10 million deaths annually. ADCs are designed to deliver potent therapeutic agents more selectively to cancer cells, while T-cell engagers are designed to activate and direct immune cells to eradicate cancer cells, offering complementary approaches to treating cancer.

"Our partnership with SBP Group brings together complementary science to broaden our development portfolio of antibody-drug conjugates and T-cell engagers. It puts our China strategy into action by connecting innovation from China with our global research and development capabilities," said Paola Casarosa, Member of the Board of Managing Directors and Head of the Innovation Unit at Boehringer Ingelheim. "Together, we aim to accelerate promising therapeutic approaches and create new treatment possibilities for people living with difficult-to-treat cancers worldwide."

Boehringer Ingelheim is building a broad and differentiated oncology portfolio spanning cancer cell-directed therapies and immuno-oncology. This relationship adds to this foundation and provides opportunities to further the ADC and T-cell engager portfolio through multiple programs and technology approaches. It underscores the company's strengthened commitment to the growing innovation ecosystem in China. Its recently opened China R&D Center in Shanghai expands early clinical development and external innovation capabilities, connecting innovation in China with its global R&D network.

"Our second partnership with Boehringer Ingelheim marks an important milestone in SBP Group's international innovation strategy and further validates our scientific capabilities in next-generation oncology. By combining our innovative platforms and early-development capabilities with Boehringer Ingelheim's global oncology expertise, we aim to maximize the potential of these programs and bring innovative treatment options to patients worldwide. We will continue to expand our global partner network and contribute high-quality innovation from China to global healthcare," said Theresa Tse, Chairwoman of SBP Group.

The collaboration covers six biologic pre-clinical programs. Five of these center on LaNova Medicines (Shanghai) Co., Ltd. ("LaNova Medicines"), a wholly owned SBP Group subsidiary. The remaining program comes from Beijing Tide Pharmaceutical Co., Ltd. ("Beijing Tide"), another SBP Group subsidiary.

Under the agreement, SBP Group will undertake early development. After agreed clinical milestones are reached, Boehringer Ingelheim may exercise options for exclusive development, manufacturing and commercialization rights: outside mainland China, Hong Kong and Macau for four programs, and worldwide for the remaining two programs.

SBP Group will receive upfront and near-term payments of US$358million and is eligible to receive potential option-exercise, development, regulatory and commercial milestone payments of US$7 billion as well as tiered royalties on potential future product sales.

Boehringer Ingelheim

Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,300 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at www.boehringer-ingelheim.com.

Sino Biopharmaceutical Limited

Sino Biopharmaceutical Limited (SBP GROUP, 01177.HK) is a leading innovation- and R&D-driven pharmaceutical group in China, with a history spanning more than three decades and a workforce of over 20,000. SBP GROUP operates a fully integrated value chain encompassing R&D, manufacturing and commercialization of innovative medicines across multiple modalities, and holds leading positions in four core therapeutic areas: oncology; hepatology and cardiometabolic diseases; respiratory and autoimmune diseases; and surgery and analgesia.

Guided by its philosophy of "Science for a Healthier World", SBP GROUP continues to advance its four strategic priorities of innovation, integration, digitalization and internationalization. It is committed to addressing unmet clinical needs, bringing safer, more effective and accessible treatments to patients worldwide, and creating shared value with its partners. Learn more at www.sbpgroup.com.

Intended Audiences Notice

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

Arla Foods Ingredients dan wheyco akan mengikuti pameran dagang bersama di Fi Europe dengan mengusung tema 'Tumbuh Lebih Kuat Bersama'

Thu, 05 Nov 2026 07:08:00 +0700

FRANKFURT, Jerman, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Arla Foods Ingredients dan wheyco, unit bisnis whey DMK Group, akan mengikuti pameran dagang bersama untuk pertama kalinya sejak perusahaan induk keduanya melakukan merger.

Pada tanggal 1 Juni, Arla Foods dan DMK Group bergabung untuk membentuk koperasi produsen susu terbesar di Eropa. Pada ajang Fi Europe (17-19 November di Frankfurt), Arla Foods Ingredients, anak perusahaan Arla Foods, akan memperlihatkan bagaimana merger itu telah memperkuat bisnis bahan baku.

Stan DMK Group dan Arla Foods Ingredients akan berlokasi saling berhadapan. Keduanya mengusung pesan 'Growing Stronger Together (Tumbuh Lebih Kuat Bersama)', dengan wheyco, anak perusahaan DMK Group, turut hadir di stan Arla Foods Ingredients.

Anne Widart, Wakil Presiden Bidang Komersial Arla Foods Ingredients, mengatakan: "Salah satu dari sekian banyak manfaat merger ini adalah terbentuknya raksasa bisnis bahan baku. Merger ini telah membuka sinergi dan peluang baru sehingga kami dapat membangun sesuatu yang bahkan lebih baik untuk masa depan. Fi Europe merupakan ajang yang tepat untuk menunjukkan ambisi bersama kami."

Awal tahun ini, Arla Foods Ingredients memperkenalkan konsep 'Targeted GLP-1 Companion Nutrition' untuk pertama kalinya, yang menunjukkan bagaimana produk kaya nutrisi dapat memenuhi kebutuhan pengguna GLP-1. Di Fi Europe, Arla Foods Ingredients akan menampilkan berbagai aplikasi produk baru, termasuk yoghurt kental yang dikonsumsi dengan sendok, yoghurt minum, minuman fermentasi tinggi protein dalam porsi kecil, serta minuman berbasis air tinggi protein dalam porsi kecil.

Konsep 'Unlock Permeate' akan menunjukkan bagaimana Variolac? Arla Foods Ingredients dapat meningkatkan efisiensi biaya dan karakteristik sensoris dalam berbagai aplikasi produk susu, roti, dan kembang gula. Diproduksi melalui proses nanofiltrasi, bahan whey permeate ini memiliki cita rasa susu yang lembut, efisiensi biaya yang tinggi, serta kandungan kalsium, magnesium, dan kalium yang tinggi.

Pengunjung juga dapat mencicipi berbagai solusi nutrisi aktif terbaru, termasuk minuman protein kocok, minuman protein berbasis air, serta AirBar, yaitu protein bar susu yang melalui proses aerasi sehingga menghasilkan tekstur ringan dan menawarkan pengalaman sensoris baru dalam kategori protein bar.

Anne Widart menambahkan: "Konsep-konsep ini mencerminkan komitmen Arla Foods Ingredients terhadap inovasi, mulai dari nutrisi pendamping GLP-1 dan nutrisi aktif hingga peningkatan cita rasa dan efisiensi biaya dengan whey permeate. Merger ini semakin memperkuat keahlian dan kapabilitas kami, sehingga kami dapat memberikan nilai tambah yang lebih besar kepada pelanggan."

Sementara itu, DMK Industry akan menampilkan portofolio bahan isian berlemak, TOPPICS, FATTICS, dan BATTICS, serta produk Susu Kental Manis melalui empat konsep sajian yang menggugah selera, yaitu cupcake dengan topping bertekstur ringan hasil aerasi, kukis cokelat karamel, fudge cokelat espresso, dan Cafe Bombon.

Portier Hotels Introduces The Arc House: A New Design-Forward Boutique Lifestyle Collection

Thu, 05 Nov 2026 06:48:00 +0700

Portier Hotels' design-forward boutique lifestyle collection, The Arc House, makes its debut with The Arc House Canggu, now open in Bali. Credit: The Arc House

Source: Portier Hotels

A more considered way to stay in the heart of things, The Arc House Canggu opens as the brand's first address, with Hong Kong and Melbourne to follow soon

HONG KONG SAR - Media OutReach Newswire - 4 November 2026 - Portier Hotels today introduces The Arc House, a new collection of design-forward boutique lifestyle hotels for travellers who want to feel closer to the character of a destination. The brand makes its debut with The Arc House Canggu, now open in Bali, and will expand to Hong Kong later this year and Melbourne in early 2027.

The Arc House is created for travellers who seek a more considered way to stay in the heart of things. Set in city-centre and neighbourhood locations, each hotel brings together bold energy, sophisticated urban living, and local insight that makes discovery feel easy. Every address is shaped by its setting, while a sociable, human-first approach to hospitality connects the collection.

Founded in 2023 and headquartered in Hong Kong, Portier Hotels is a hospitality group for those who value connection, discovery and a stronger sense of place over convention. With a portfolio of distinctive hotel brands, the group brings design, operations and guest experience together from concept through to everyday delivery, guided by a simple belief: luxury lives in the execution.

Edward McKenna, Co-Founder of Portier Hotels, said: "Portier Hotels was founded with a simple ambition of creating hospitality brands with a clear point of view and the discipline to deliver on it every day. Asia-Pacific is a region of very different travel cultures, and increasingly guests expect hotels to reflect that richness. They look for design, service and food that bring them closer to a place, rather than offering the same experience in every destination. That's the differentiation that Portier Hotels offers through our brands."

Located at the Creative Pulse of Bali, The Arc House Canggu Welcomes Guests

The Arc House Canggu is the first expression of the brand's approach to locally connected, design-forward hospitality. Set close to Batu Bolong Beach, the boutique hotel is positioned within Canggu's evolving mix of contemporary dining, independent retail, wellness and after-hours energy. It gives guests a well-placed base from which to enter the neighbourhood, while offering a clear, personal place to return to as the day moves on.

Karen Choi, Co-Founder and Head of Architecture, Portier Hotels, said: "We want every The Arc House to feel like part of one collection, without ever feeling repeated. A shared design language pairs minimalist interiors with arches as an architectural signature, but each address is informed by the building, the neighbourhood and the creative life around it. In Canggu, that means a contemporary, minimalist setting with locally sourced artwork that makes the experience feel specific to this place."

The design brings a calm counterpoint to the rhythm outside. Clean, minimalist spaces are given depth through a refined material palette, tactile details and commissioned artwork. Rather than creating a standard hotel environment, it is designed to move with the way guests spend time in Canggu: easy to arrive at, open to the day ahead and perfectly comfortable to make staying in feel equally appealing.

The hotel's 19 private-pool suite villas provide a more personal setting within the property. Each offers guests their own pool and the space to reset between a beach afternoon, a long lunch, a class, a dinner reservation or an unplanned evening in. The restaurant and rooftop infinity pool bring a more shared, open-air rhythm to the experience, places to meet, linger and feel part of the life of the hotel without needing a formal schedule.

At MYKAZA, the Indo-Japanese dining concept within the hotel blends Japanese techniques and Balinese flavours in a restaurant made for guests and the neighbourhood alike. The rooftop pool offering panoramic sunset views, breakfast delivered to the villa and wellness programming complete an experience designed to feel easy and personal.

New Urban Addresses Debut Later This Year and Early Next Year

Later this year, The Arc House Hong Kong will open at 148 Wellington Street, Central, introducing the brand to one of Asia's most layered urban districts. The 24-room property will place guests close to Central's art, heritage, dining and city rhythm, with a design-led stay made for travellers who want to be in the middle of what is happening.

Thoughtfully planned rooms, an artful Lounge, Rooftop terrace and gym will provide an easy place to meet, pause or reset between days in the city. Its restaurant, One Forty Eight Wellington, will bring Cantonese flavours and drinks to a shared table for locals and travellers, with further details to be announced ahead of opening.

The Arc House will continue its expansion with a Melbourne opening planned for early 2027. The future hotel will bring the collection's design-forward, locally responsive approach to another dynamic city setting with a 43-room boutique hotel. Further details on its location, design and guest experience will be announced closer to opening.

Nikola Sasic, President, APAC, Portier Hotels, said: "The way guests use The Arc House is what brings the brand to life. Programming gives them a simple way into the food cultures, people and places that shape a neighbourhood, from a shared experience at the hotel to a recommendation worth following. Canggu is the beginning of a carefully considered rollout for The Arc House. Hong Kong and Melbourne will answer to very different city rhythms, which is exactly why they are right for the collection."

* These conceptual design drawings are computer renderings which represent the artist's impressions and are for reference only. All such renderings may not reflect the actual appearance, condition, view or surrounding environment of the property.

About The Arc House

The Arc House is a collection of design-forward boutique lifestyle hotels by Portier Hotels. Set in city-centre and neighbourhood locations, each hotel brings together a bold energy, sophisticated urban living and local insight that makes discovery feel easy. Each address in the collection is individually shaped by its setting and united by a sociable, human-first approach to hospitality. The Arc House offers a more considered way to stay in the heart of things.

About Portier Hotels

Founded in 2023, Portier Hotels is a full-service boutique hospitality group spanning development, operations and management. The group's portfolio comprises two distinct brands, je ne sais quoi and The Arc House, each with its own identity and united by a shared approach to human-first hospitality. With properties in Asia-Pacific, Portier Hotels combines purposeful minimalist design with instinctive, personalised service and a responsible sense of place. From development through daily operations, the group focuses on the details that make a stay feel effortless, comfortable and genuinely personal. Its defining belief is simple: luxury is in the execution.

The issuer is solely responsible for the content of this announcement.

Hashtags: #PortierHotels #TheArcHouse #BoutiqueLifestyle

mamun raises US$3 million to finance cross-border trade between the Gulf and Asia

Thu, 05 Nov 2026 06:42:00 +0700

mamun co-founders, left to right: Ahmed Al-Issaei (Co-Founder & CTO), Saleh Al Tamami (Co-Founder & CEO), Mohammed Al Tamami (Co-Founder & CCO)

The seed round scales mamun's capital infrastructure for trade finance along the Greater Bay Area - Oman - UAE corridor - anchored in Muscat, Abu Dhabi and Hong Kong SAR.

MUSCAT, ABU DHABI/HONG KONG SAR - Media OutReach Newswire - 4 November 2026 - mamun, the Sharia-compliant platform building capital infrastructure for trade finance, has raised a US$3 million seed round led by Phaze Ventures through its Oman Fund, with participation from Jasoor Ventures.

An exporter in Muscat ships today and gets paid in 60 to 90 days. Banks rarely bridge that gap, as they usually rely on a long financial track record that many small exporters find hard to provide. The Asian Development Bank puts the global trade finance gap at US$2.5 trillion, and 41% of SME trade finance applications are turned down.

mamun's AI-native underwriting assesses the company behind the trade, alongside the shipment itself: the contract, the buyer, the trade documents and the trading history between them. Its origination engine finds and screens that trade as it forms. Then investors on the platform finance the gap.

The hard part is the border. A cross-border transaction spans two regulators, two banking systems and two legal regimes, with settlement that has to land in another jurisdiction on time, and the collateral is in motion, travelling with the goods along the route.

That complexity is why most of the region's financing platforms have stayed domestic, and it is mamun's moat. The platform was built across the corridor: an FSA-regulated home and origination base in Muscat; Abu Dhabi for Gulf capital and UAE flows; and Hong Kong SAR, the financing gateway of the Belt and Road Initiative, for the Greater Bay Area and the Gulf?Asia trade routes.

Roughly 40% of the platform's trade finance settlements already clear through Hong Kong-based financial institutions and businesses.

mamun's licence sits within the FSA's crowdfunding framework, which allows the platform to bring in investors from inside and outside the Sultanate, and to finance companies inside and outside the Sultanate, subject to the platform's eligibility criteria and the laws applicable in each investor's country.

The corridor is growing. Oman's non-oil exports ran about 10% higher year-on-year through the first seven months of 2026 and re-exports 13.6% higher, with the UAE its largest non-oil trading partner. New corridors bring new counterparties: businesses trading together for the first time, with no shared history for a lender to underwrite against.

The round brings together capital from Oman and the UAE: Phaze Ventures invests through its Oman Fund, dedicated to homegrown, AI-enabled Omani businesses, and Jasoor Ventures is an early-stage venture capital firm backing technology founders across the Middle East, North Africa, and Turkey.

The US$3 million will scale that AI-native origination and underwriting, growing the volume of trade the platform can originate, assess and finance along the Greater Bay Area - Oman - UAE corridor. It is where the industry is heading: 84% of banks in the Asian Development Bank's January 2026 survey already apply AI to trade finance risk. mamun was built that way from origination onward.

"The businesses moving goods between the Gulf and Asia are growing faster than the financing behind them. We built mamun in Muscat, under Omani regulation, to serve trade along the corridor between the Gulf and Asia. This round scales that engine - and the corridor it serves."

- Saleh Al Tamami ? Co-Founder & CEO, mamun

"Our thesis is backing the homegrown companies that turn Oman's diversification agenda into regional infrastructure. mamun is exactly that - structured across the corridor, and built by a team that has executed quietly and precisely. It is a natural commitment from the Oman Fund."

- Abdullah Al Shaksy ? Co-Founder & CEO, Phaze Ventures

mamun was founded by Saleh Al Tamami, Co-Founder & CEO, Mohammed Al Tamami, Co-Founder & Chief Commercial Officer, and Ahmed Al-Issaei, Co-Founder & CTO, and was named a Rising Star on the Deloitte Technology Fast 50 Middle East 2025, ranking 26th.

This announcement is for information only and does not constitute an offer or invitation to invest. mamun is not licensed by the Securities and Futures Commission of Hong Kong (SFC).

ABOUT mamun

mamun builds capital infrastructure for trade finance. The platform is Sharia-compliant, licensed and regulated by the Financial Services Authority of Oman (FSA Licence CMI051). This licence covers the Omani entity only. The group also has entities in Abu Dhabi and Hong Kong SAR. It connects businesses and investors to finance cross-border trade - exports, imports and the working capital that moves goods between markets.

ABOUT PHAZE VENTURES

Founded in 2018, Phaze Ventures is Oman's oldest private venture capital firm. Headquartered in Oman, with a presence in Saudi Arabia and the UAE, it backs early-stage AI and deeptech companies globally and homegrown technology businesses through the Oman Fund.

ABOUT JASOOR VENTURES

Jasoor Ventures, meaning "courageous" in Arabic, is an ADGM-based venture capital firm, investing across the Middle East, North Africa, and Turkey.

The issuer is solely responsible for the content of this announcement.

Hashtags: #mamun

CGTN: Global Mayors Dialogue reaffirms China's commitment to openness

Thu, 05 Nov 2026 06:32:00 +0700

BEIJING, Nov. 03, 2026 (GLOBE NEWSWIRE) -- The main event of the 2026 Global Mayors Dialogue ? Ningbo opened in port city Ningbo on Tuesday, bringing together representatives from 15 countries and 20 international cities.

Themed "Openness and Connectivity for Shared Opportunities," it produced 14 cooperation agreements and the Ningbo Consensus on Cooperative Development, underscoring the role of cities as engines of open trade and mutual benefit.

The signed projects span sister-city exchanges, trade and investment, science and education, culture and tourism. "The city's opening up is not a one-way going out but a two-way embedding into global industrial and innovation chains," Ningbo Mayor Shen Mingquan said.

As one of China's first coastal cities to open to the outside world, Ningbo maintains economic and trade ties with more than 220 countries and regions globally.

This global integration has shown significant results. In 2024, a delegation from Ningbo went to meet the Suez Canal authorities in Egypt, and Ningbo-based Dashun Fur invested $40 million in the Suez Canal Economic Zone, their cooperation expanding from traditional textiles to modern logistics. Products such as milk powder from New Zealand and Moroccan dates are popular among Ningbo residents, and the Maldives is one of their top 10 outbound tourist destinations.

China remains the world's largest goods trader and second largest importer, and a major trade partner for more than 150 countries and regions. Customs data show China's goods trade reached 45.47 trillion yuan ($6.51 trillion) in 2025, up 3.8% year on year, with exports of 26.99 trillion yuan ($4.06 trillion) and imports of 18.48 trillion yuan ($2.78 trillion).

Trade with Belt and Road partners accounted for 51.9% of China's total foreign trade. These figures underscore a basic reality: China's growth needs the world, and the world needs China for global prosperity.

The dialogue in Ningbo repeatedly returned to the choice between "building walls" and "building bridges." At Tuesday's event, Auckland Mayor Wayne Brown shared how a South Pacific gateway has turned distance into openness. Karimi Said, Mayor of Moroccan city Errachidia, cited oasis agriculture and dates as links to global markets.

Cultural exchanges during the event - including a copper-plate document from the Maldives' Laamu Atoll, a scarab from Suez, and Norman candy from Saint-?tienne in France - were placed on equal footing with commercial contracts, reflecting the Consensus's emphasis on people-to-people bonds.

The Ningbo Consensus commits participants to deeper industrial collaboration, open trade, and people-to-people exchange. It aligns with the spirit of a community with a shared future for humanity, advocating for a world where cities support one another through mutual trust and win-win cooperation.

By connecting ports, supply chains, and people - both in person and through digital platforms - the 20 cities sent a clear message: Openness and connectivity, not isolation, remains the surest path to shared opportunity.

https://news.cgtn.com/news/2026-11-03/Global-Mayors-Dialogue-reaffirms-China-s-commitment-to-openness-1RM72ClE0rC/p.html

Helm Expands into Australia with Presence in Sydney

Wed, 04 Nov 2026 21:23:00 +0700

International private markets technology and infrastructure company establishes local presence to support wealth firms, asset managers and ecosystem firms across Australia and New Zealand.

NEW YORK AND SYDNEY, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Helm, the international private markets operating system backed by iAltA, today announced it has expanded into Sydney to support its growth across Australia and New Zealand.

The expansion establishes a local presence for Helm as product manufacturers, wealth firms and service providers across the region increasingly seek more efficient ways to structure, distribute and manage private market investments. James Wilkinson, former General Manager at iPartners, will lead Helm in the region.

Private markets are continuing to grow in scale across asset classes, investment structures and distribution channels, creating new opportunities for end investors but adding complexity for the firms that serve them. In Australia and New Zealand, that evolution is increasing the need for enterprise-grade infrastructure that can connect historically fragmented processes and point solutions across the investment lifecycle.

"Australia has developed a sophisticated and rapidly evolving private markets ecosystem, and we see a significant opportunity to support those firms that are broadening access to private markets," said Gareth Lewis, Chief Business Officer of Helm. "Establishing a local presence allows us to work more closely with clients and partners in the region and bring technology and expertise that can help them manage the increasing complexity of private market investing."

Helm helps private market participants reduce that complexity by connecting product and distribution with investor onboarding, transaction workflows and reporting. Its configurable technology is designed to help firms build.

The expansion to Sydney will give Helm an on-the-ground presence to work with clients and partners and build relationships across the Australian and New Zealand private markets ecosystem.

"Australia and New Zealand represent an exciting opportunity for Helm because of both the maturity of the wealth channel and the growing advisor and investor interest in private markets," Wilkinson said. "Having a team on the ground means we can combine Helm's global capabilities with a real understanding of how firms here operate, what their clients expect and simplify their processes to operate more efficiently so they can focus on what they do best."

About Helm

Backed by iAltA, Helm is a private markets operating system that helps product manufacturers and investment firms simplify capital raising and investor workflows. Supporting a range of use cases, Helm is designed to reduce operational friction and improve the delivery of private market offerings to investors. Visit www.helmmarkets.com

About iAltA

Launched in 2025 by founding partners Scott Ganeles, Bill Sherman, Bill Crager, and Laurence Tosi, iAltA is a holding company founded by experienced operators to address systemic gaps in private markets infrastructure. Incubated and backed by WestCap, iAltA builds platforms that unify fragmented workflows, elevate transparency, and empower product manufacturers and investment firms throughout the investment lifecycle. Visit www.ialta.com

Iveco Group 2026 Third Quarter Results

Wed, 04 Nov 2026 21:17:00 +0700

A quarter marked by continued efforts in quality initiatives,

with revenue growth offset by a temporary product mix impact

Following the successful completion of the tender offer,

Iveco Group is now part of Tata Motors

EU-IFRS FINANCIAL MEASURES					NON-EU-IFRS FINANCIAL MEASURES ⁽¹⁾
	(EUR million)	Q3 2026	Q3 2025	Change		(EUR million)	Q3 2026	Q3 2025	Change
	Consolidated EBIT	11	91	-80		Adjusted EBIT	30	111	-81
	of which EBIT of Industrial Activities	(18)	56	-74		of which Adjusted EBIT of Industrial Activities	-	76	-76
	Profit/(loss) for the period	(45)	16	-61		Adjusted Net Income (Loss)	(32)	40	-72
	Diluted EPS EUR	(0.17)	0.06	-0.23		Adjusted Diluted EPS EUR	(0.12)	0.15	-0.27
	Cash flow from operating activities	(113)	102	-215		Free Cash Flow of Industrial Activities	(656)	(513)	-143
	Cash and cash equivalents⁽²⁾	1,786	2,514	-728		Available Liquidity⁽²⁾	3,713	4,432	-719

In the third quarter, Iveco Group recorded consolidated revenues of EUR3.16 billion, an increase of 1.4%, and Industrial Activities net revenues of EUR3.09 billion (+1.5%). Industrial Activities Adjusted EBIT was nil, mainly on the back of continued focus on quality, as planned, negative product mix and inflation impact. Free Cash Flow registered an outflow of EUR656 million, in line with seasonality typical of this quarter, while Available Liquidity remained solid at EUR3.7 billion as of 30th September 2026, including EUR1.9 billion of undrawn committed facilities.

Truck confirmed its leadership position in the chassis cab segments and further reinforced it in the upper end of the light commercial vehicle (LCV) market. Compared to the third quarter of 2025, European industry volumes were largely stable across all ranges. European order intake in medium - and heavy-duty remained solid, increasing 23% and remained broadly flat in light-duty. While profitability was affected by competitive pressure in LCV, driven by flattish industry demand, the business unit maintained disciplined pricing in European heavy-duty vehicles.

IVECO BUS confirmed its place among the leaders in the European e-bus market and consolidated its strong market share in the City and Intercity segments. Due to the unfavorable comparison to the same quarter of 2025, when Intercity demand peaked, deliveries fell 6%. Profitability was also affected by a negative product mix.

In Powertrain, overall engine volumes increased by 5% compared to the third quarter of 2025, due to a steady increase in European small-engine deliveries across off- and on-road applications. Fewer large-engine deliveries, particularly in the Americas, affected profitability; an impact that was partially offset by disciplined cost control and continued operational efficiencies. Continuous efforts in quality initiatives, as planned, have negatively affected third quarter's profitability across business units.

Looking ahead, despite weaker industry demand for LCVs, macroeconomic uncertainties, a negative product mix and continuous effort in quality initiatives across business, the Company expects profitability to recover in Q4 2026. Industrial Activities free cash flow generation is expected to be solid in the last quarter of the year, as per usual seasonality.

"In the third quarter, we continued to prioritise quality throughout the company, dedicating additional resources in line with the strategy we set for the year. This deliberate choice weighed on profitability, along with an unfavourable product mix across business units. Our efforts in quality reached their peak during the quarter and, from now onwards, will gradually decrease. Their benefits will become increasingly visible in our performance and will eventually make a positive contribution to our results. Overall, our revenues were slightly up versus the previous year, demonstrating the solid competitiveness of our products."

Olof Persson, Chief Executive Officer

Notes:

Iveco Group consolidated financial results included in this press release are prepared in accordance with EU-IFRS.

(*) 2026 and 2025 financial data shown in this press release refer to Continuing Operations only (ie. excluding Defence business), unless otherwise stated. In particular, on 18th March 2026, Iveco Group transferred the full ownership of its Defence business (IDV and ASTRA brands) to Leonardo S.p.A., as per the terms of the agreement announced on 30th July 2025. In accordance with IFRS 5 - Non-current Assets Held for Sale and Discontinued Operations, as the sale became highly probable in July 2025, the Defence business met the criteria to be classified as a disposal group held for sale since that date; it also met the criteria to be classified as Discontinued Operations.

(1) Non-EU-IFRS financial measures: refer to the "Non-EU-IFRS Financial Information" section of this press release for information regarding non-EU-IFRS financial measures. Refer to the specific table in the "Other Supplemental Financial Information" section of this press release for the reconciliation between the non-EU-IFRS financial measure and the most comparable EU-IFRS financial measure.

(2) Comparison vs 30th June 2026.

Q3 2026 Performance and Results by Business Unit

Consolidated revenues amounted to EUR3,158 million compared to EUR3,115 million in Q3 2025, up 1.4%. Net revenues of Industrial Activities were EUR3,091 million compared to EUR3,044 million in Q3 2025, up 1.5%, mainly due to higher volumes in Europe and favourable foreign exchange impacts, partially offset by lower pricing.

Adjusted EBIT was EUR30 million compared to EUR111 million in Q3 2025, with a margin of 0.9% (3.6% in Q3 2025). Adjusted EBIT of Industrial Activities was nil compared to EUR76 million in Q3 2025, mainly due to unfavourable production costs due to strengthened quality focus, Truck net pricing, and negative product mix across businesses.

Adjusted Net Loss was EUR32 million (Adjusted Net Income of EUR40 million in Q3 2025) and Adjusted Diluted Earnings per share was negative EUR0.12 (positive EUR0.15 in Q3 2025).

Net financial expenses amounted to EUR72 million compared to EUR58 million in Q3 2025, mainly due to a negative impact of hyperinflation accounting in T?rkiye and higher borrowing costs.

Reported income tax was EUR16 million, with an Adjusted Effective Tax Rate (Adjusted ETR(1)) of 24% in Q3 2026, which reflects the different tax rates applied in the jurisdictions where the Group operates and some discrete items.

Free Cash Flow of Industrial Activities was negative at EUR656 million compared to negative EUR513 million in Q3 2025, mainly due to working capital absorption and higher investments.

Available Liquidity was EUR3,713 million as of 30th September 2026, including EUR1,900 million of undrawn committed facilities.

Truck

	Q3 2026	Q3 2025	Change		The European Truck market was down 2% year-over-year, with Light-Duty Vehicles (LCV) down 4% and Medium- and Heavy-Duty Trucks (M&H) in line with Q3 2025. The South American Truck market was aligned with the previous year. Iveco Group deliveries were up 12% vs Q3 2025 in Europe (up 9% and 22% in LCV and M&H, respectively) and were up 4% in South America (up 31% in LCV and down 13% in M&H). Worldwide Truck book-to-bill was 0.94 at the end of the quarter. Net Revenues were EUR 2,099 million, up 4.5% compared to Q3 2025, mainly driven by higher volumes. The Adjusted EBIT was EUR 10 million compared to EUR 59 million in Q3 2025, primarily driven by negative product mix and net pricing, as well as strengthened focus on quality. The Adjusted EBIT margin was at 0.5% (2.9% in Q3 2025).
Net revenues (EUR million)	2,099	2,008	+4.5%
Adjusted EBIT (EUR million)	10	59	-49
Adjusted EBIT margin	0.5%	2.9%	-240	bps

Notes:

Bus

	Q3 2026	Q3 2025	Change		Bus registrations were down 1% in Europe and were flat in South America compared to Q3 2025. Iveco Group deliveries were down 7% and 5% in Europe and South America, respectively. Net Revenues were down 5.6% in the quarter, driven by lower volumes and mix. The Adjusted EBIT was EUR 5 million compared to EUR 29 million in Q3 2025, resulting from negative product mix and continuous quality initiatives. The Adjusted EBIT margin was at 0.7% (4.0% in Q3 2025).
Net revenues (EUR million)	679	719	-5.6%
EUR djusted EBIT (EUR million)	5	29	-24
Adjusted EBIT margin	0.7%	4.0%	-330	bps

Powertrain

	Q3 2026	Q3 2025	Change		Powertrain Net Revenues were ?810 million, up 8.7% compared to Q3 2025, due to higher small-engine deliveries. Sales to external customers accounted for 48% (49% in Q3 2025). The Adjusted EBIT was EUR 24 million compared to EUR 38 million in Q3 2025, primarily driven by negative product mix and higher product costs for increased resources dedicated to quality. The Adjusted EBIT margin was at 3.0% (5.1% in Q3 2025).
Net revenues ( million)	810	745	+8.7%
EUR djusted EBIT (EUR million)	24	38	-14
Adjusted EBIT margin	3.0%	5.1%	-210	bps

Financial Services

	Q3 2026	Q3 2025	Change	Financial Services Net Revenues were EUR 110 million, in line with Q3 2025. The Adjusted EBIT was at EUR 30 million compared to EUR 35 million in Q3 2025, due to deteriorated collection performances. The end of period managed portfolio for Iveco Group (including unconsolidated joint ventures) was EUR 7,846 million at the end of the quarter (of which retail was 43% and wholesale 57%), up EUR 316 million compared to 30^thSeptember 2025. The receivable balance greater than 30 days past due as a percentage of the on-book portfolio was 2.6% (2.1% as of 30^thSeptember 2025).
Net revenues (EUR million)	110	111	-0.9%
Adjusted EBIT (EUR million)	30	35	-5
Equity at quarter end (EUR million)	806	830	-24
Retail loan originations (EUR million)	421	389	+32

Iveco Group Results for the Nine Months ended 30^th September 2026

EU-IFRS FINANCIAL MEASURES					NON EU-IFRS FINANCIAL MEASURES⁽¹⁾
	(EUR million)	Q3 YTD 2026	Q3 YTD 2025	Change		(EUR million)	Q3 YTD 2026	Q3 YTD 2025	Change
	Consolidated EBIT	23	314	-291		Adjusted EBIT	106	399	-293
	of which EBIT of Industrial Activities	(68)	216	-284		of which Adjusted EBIT of Industrial Activities	14	301	-287
	Profit/(loss) for the period	(123)	109	-232		Adjusted Net Income/(Loss)	(60)	179	-239
	Diluted EPS EUR	(0.47)	0.40	-0.87		Adjusted diluted EPS EUR	(0.23)	0.66	-0.89
	Cash flow from operating activities	(352)	(3)	-349		Free Cash Flow of Industrial Activities	(1,382)	(1,241)	-141
	Cash and cash equivalents⁽²⁾	1,786	2,953	-1,167		Available Liquidity⁽²⁾	3,713	5,192	-1,479

Truck

	Q3 YTD 2026	Q3 YTD 2025	Change
Net revenues (EUR million)	6,352	6,317	+0.6%
Adjusted EBIT (EUR million)	13	246	-233
Adjusted EBIT margin	0.2%	3.9%	-370	bps

Bus

	Q3 YTD 2026	Q3 YTD 2025	Change
Net revenues (EUR million)	2,214	1,948	+13.7%
Adjusted EBIT (EUR million)	35	97	-62
Adjusted EBIT margin	1.6%	5.0%	-340	bps

Powertrain

	Q3 YTD 2026	Q3 YTD 2025	Change
Net revenues (EUR million)	2,541	2,407	+5.6%
Adjusted EBIT (EUR million)	85	115	-30
Adjusted EBIT margin	3.3%	4.8%	-150	bps

Financial Services

	Q3 YTD 2026	Q3 YTD 2025	Change
Net revenues (EUR million)	322	338	-4.7%
Adjusted EBIT (EUR million)	92	98	-6

Notes:

(2) Comparison vs 31st December 2025.

Non-EU-IFRS Financial Information

Iveco Group monitors its operations through the use of several non-EU-IFRS financial measures including Adjusted EBIT, Adjusted EBIT margin, Adjusted Net Income/(Loss), Adjusted Diluted EPS, Adjusted Income Taxes, Adjusted Effective Tax Rate, Free Cash Flow of Industrial Activities, Net Cash (Debt) and Net Cash (Debt) of Industrial Activities, and Available Liquidity. Iveco Group's management believes those measures provide useful and relevant information regarding Iveco Group's operating results and enhance the readers' ability to assess Iveco Group's financial performance and financial position. Management uses these non-EU-IFRS financial measures to monitor the underlying performance of Iveco Group's business and operations, to identify operational trends, as well as to make decisions regarding future spending, resource allocations and other operational decisions as they provide additional transparency with respect to Iveco Group's core operations. These non-EU-IFRS financial measures have no standardised meaning under EU-IFRS and are unlikely to be comparable to other similarly titled measures used by other companies and are not intended to be substitutes for measures of financial performance and financial position as prepared in accordance with EU-IFRS. Iveco Group's non-EU-IFRS financial measures are defined as follows:

Adjusted EBIT: is defined as EBIT before restructuring costs and non-recurring items, if any. In particular, non-recurring items are specifically disclosed items that management considers rare or discrete events that are infrequent in nature and not reflective of ongoing operational activities. The performance of Iveco Group is reviewed based on the Adjusted EBIT, which the management believes more fully reflects Iveco Group's profitability, and, as such, Iveco Group uses Adjusted EBIT for internal reporting to assess performance as part of the forecasting, budgeting and decision-making process as it provides additional transparency regarding Iveco Group's underlying operating performance. The management believes Adjusted EBIT is useful because it excludes items that management believes are not indicative of Iveco Group's underlying operating performance between periods. The management also believes that Adjusted EBIT is useful for investors and analysts to better understand how management assesses Iveco Group's underlying operating performance on a consistent basis. Accordingly, Iveco Group believes that Adjusted EBIT provides useful information to third party stakeholders in understanding and evaluating Group's operations;

Adjusted EBIT margin; is computed by dividing a) Adjusted EBIT by b) Net revenues;

Adjusted Net Income/(Loss): is defined as profit/(loss) for the period, before restructuring costs and non-recurring items, if any, net of the related income tax effect. In particular, non-recurring items are specifically disclosed items that management considers rare or discrete events that are infrequent in nature and not reflective of ongoing operational activities. Iveco Group uses Adjusted Net Income/(Loss) to assess performance as part of its decision-making process as it provides additional insight into Iveco Group's underlying overall performance, net of income tax. The management believes that Adjusted Net Income/(Loss) is also useful for investors and analysts to better understand how management assesses Iveco Group's underlying overall performance on a consistent basis. Accordingly, Iveco Group believes that Adjusted Net Income/(Loss) provides useful information to third party stakeholders in understanding and evaluating Group's operations;

Adjusted Diluted EPS: is computed by dividing Adjusted Net Income/(Loss) attributable to Iveco Group N.V. by a weighted-average number of Common Shares outstanding during the period that takes into consideration potential Common Shares outstanding deriving from the Iveco Group share-based payment awards, when inclusion is not anti-dilutive. When Iveco Group provides guidance for adjusted diluted EPS, the Group does not provide guidance on an earnings per share basis because the EU-IFRS measure will include potentially significant items that have not yet occurred and are difficult to predict with reasonable certainty prior to year-end;

Adjusted Income Taxes: is defined as income taxes less the tax effect of restructuring expenses and non-recurring items, and non-recurring tax charges or benefits;

Adjusted Effective Tax Rate (Adjusted ETR): is computed by dividing a) Adjusted Income Tax (expense) benefit by b) Adjusted Profit/(Loss) before taxes. Adjusted Income Tax (expense) benefit represents income tax (expense) benefit, adjusted for the income tax (expense) benefit of restructuring costs and non-recurring items, if any, as well as any non-recurring tax expenses or benefits. Adjusted Profit/(Loss) before taxes represents profit/(loss) before taxes of the applicable period, adjusted for restructuring costs and non-recurring items, if any. Adjusted ETR fully reflects Iveco Group's level of taxation, based on Group's Profit/(Loss) before taxes, removing extraordinary and non-recurring items. The management believes that this is useful for investors and analysts to better understand Iveco Group's level of taxation on a consistent basis and enables them to compare Iveco Group's level of taxation with that of other companies;

Free Cash Flow of Industrial Activities (or Industrial Free Cash Flow): refers to Industrial Activities, only, and is computed as consolidated cash flow from operating activities less: cash flow from operating activities of Financial Services; investments of Industrial Activities in property, plant and equipment and intangible assets; as well as other changes and intersegment eliminations. Iveco Group views Free Cash Flow as a useful measure for measuring its cash generation ability;

Net Cash (Debt) and Net Cash (Debt) of Industrial Activities: Net Cash (Debt) is defined as total Debt (including debt payable to CNH deriving from financing activities and sale of trade receivables) plus Derivative liabilities, net of Cash and cash equivalents, Derivative assets and other current financial assets (primarily current securities, short-term deposits and investments towards high-credit rating counterparties) and financial receivables from CNH deriving from financing activities and sale of trade receivables. Iveco Group provides the reconciliation of Net Cash (Debt) to Total (Debt), which is the most directly comparable EU-IFRS financial measure included in the Group's Consolidated Statement of Financial Position. Due to different sources of cash flows used for the repayment of the debt between Industrial Activities and Financial Services (by cash from operations for Industrial Activities and by collection of financing receivables for Financial Services), management separately evaluates the cash flow performance of Industrial Activities using Net Cash (Debt) of Industrial Activities; and

Available Liquidity: is defined as cash and cash equivalents, including restricted cash, undrawn medium-term unsecured committed facilities, other current financial assets (primarily current securities, short-term deposits and investments towards high-credit rating counterparties), and financial receivables from CNH deriving from financing activities and sale of trade receivables.

Forward-looking statements

Statements other than statements of historical fact contained in this earning release, including competitive strengths; business strategy; future financial position or operating results; budgets; projections with respect to revenue, income, earnings (or loss) per share, capital expenditures, dividends, liquidity, capital structure or other financial items; costs; and plans and objectives of management regarding operations and products, are forward-looking statements. These statements may include terminology such as "may", "will", "expect", "could", "should", "intend", "estimate", "anticipate", "believe", "outlook", "continue", "remain", "on track", "design", "target", "objective", "goal", "forecast", "projection", "prospects", "plan", or similar terminology. Forward-looking statements are not guarantees of future performance. Rather, they are based on current views and assumptions and involve known and unknown risks, uncertainties and other factors, many of which are difficult to predict and/or are outside the Company's control. If any of these risks and uncertainties materialise (or they occur with a degree of severity that the Company is unable to predict) or other assumptions underlying any of the forward-looking statements prove to be incorrect, including any assumptions regarding strategic plans, the actual results or developments may differ materially from any future results or developments expressed or implied by the forward-looking statements. Factors, risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements include, among others: the continued uncertainties related to the unknown duration and economic, operational and financial impacts of ongoing and/or threatened international conflicts and geopolitical tensions; vulnerability to cybersecurity or data privacy incidents, also due to potential massive availability of Generative Artificial Intelligence; the many interrelated factors that affect consumer confidence and worldwide demand for capital goods and capital goods-related products, including demand uncertainty caused by current macroeconomic and geopolitical issues; changes in government policies regarding banking, monetary and fiscal policy; legislation, particularly pertaining to capital goods-related issues such as the environment, debt relief and subsidy program policies, trade and commerce and infrastructure development; government policies on international trade and investment, including sanctions, import quotas, capital controls and tariffs; volatility in international trade caused by the imposition of tariffs, sanctions, embargoes, and trade wars; actions of competitors in the various industries in which we compete; development and use of new technologies and technological difficulties; the interpretation of, or adoption of new, compliance requirements with respect to engine emissions, safety or other aspects of our products; production difficulties, including capacity and excess inventory levels; labour relations; interest rates and currency exchange rates; inflation and deflation; energy prices; our ability to obtain financing or to refinance existing debt; price pressure on new and used vehicles; the resolution of pending litigation and investigations on a wide range of topics, including dealer and supplier litigation, follow-on private litigation in various jurisdictions after the settlement of the EU antitrust investigation of the Iveco Group announced on 19 July 2016, intellectual property rights disputes, product warranty and defective product claims, and emissions and/or fuel economy regulatory and contractual issues; security breaches, cybersecurity attacks, technology failures, and other disruptions to the information technology infrastructure of Iveco Group and its suppliers and dealers; security breaches with respect to our products; further developments of geopolitical threats which could impact our operations, supply chains, distribution network, as well as negative evolutions of the economic and financial conditions at global and regional levels; political and civil unrest; volatility and deterioration of capital and financial markets, including other pandemics, terrorist attacks or acts of war in Europe and elsewhere; our ability to realise the anticipated benefits from our business initiatives as part of our strategic plan; our failure to realise, or a delay in realising, all of the anticipated benefits of our acquisitions, joint ventures, strategic alliances or divestitures and other similar risks and uncertainties, and our success in managing the risks involved in the foregoing.

Forward-looking statements are based upon assumptions relating to the factors described in this earnings release, which are sometimes based upon estimates and data received from third parties. Such estimates and data are often revised. Actual results may differ materially from the forward-looking statements as a result of a number of risks and uncertainties, many of which are outside Iveco Group's control. Except as otherwise required by applicable rules, Iveco Group expressly disclaims any intention to provide, update or revise any forward-looking statements in this announcement to reflect any change in expectations or any change in events, conditions or circumstances on which these forward-looking statements are based. Further information concerning Iveco Group, including factors that potentially could materially affect Iveco Group's financial results, is included in Iveco Group's reports and public filings under applicable regulations.

About Iveco Group

Iveco Group N.V. (EXM: IVG) is a global player in the automotive industry, built on a strong Italian heritage and with a consolidated international reach. The Group channels decades of engineering excellence and innovation into sustainable mobility and customer driven technologies. Its five brands play a leading role in their respective domains: IVECO, a pioneering commercial vehicles brand offering heavy, medium and light duty trucks; FPT, a global leader in advanced powertrain technologies in the agriculture, construction, marine, power generation and commercial vehicles sectors; IVECO BUS and HEULIEZ, renowned for their mass transit, premium bus and coach solutions; and IVECO CAPITAL, the Group's financing arm supporting them all. Iveco Group employs 33,000 people and operates 16 industrial sites and 22 R&D centres. Further information is available on the Company's website www.ivecogroup.com.

UPDATE -- Hotel101 Global Enters Egypt - Its First Entry in the African Continent

Wed, 04 Nov 2026 20:36:00 +0700

SINGAPORE, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Hotel101 Global Holdings Corp. (NASDAQ Ticker: HBNB) ("Hotel101" or "Hotel101 Global"), a leading asset-light, prop-tech hospitality platform pioneering a globally standardized "condotel" business model, listed on the Nasdaq Stock Exchange and a subsidiary of Philippine-listed DoubleDragon Corporation (PSE Ticker: DD), announces the signing of definitive binding agreements for a country-wide joint venture for the expansion of Hotel101 in Egypt, starting with the development of an approximately 750-room Hotel101 in Cairo, Egypt.

This expansion marks a significant milestone in the company's global growth strategy, bringing its novel, globally standardized condotel business model to one of the Middle East and Africa's most dynamic capital cities and a major cultural tourism gateway.

The country-wide joint venture for the expansion of Hotel101 into Egypt is between Hotel101 Global Pte. Ltd. and IGI Holding's affiliates, WNTR Property and WNTR Hospitality. The Sheta family has built and led Egypt's IGI Group since 1942. Over successive generations, the group has grown into a diversified enterprise with interests spanning textiles, FMCG, food and beverage, heavy industry, petroleum, construction, hospitality and real estate. Building on this foundation, IGI is now expanding into new sectors, with investments in industrial minerals and digital infrastructure. IGI Developments, the group's real-estate arm, has been a pioneer of integrated residential compounds in Egypt since the mid-1990s. Over more than 30 years it has delivered multiple integrated communities; it holds a land portfolio of up to approximately 2.5 million square meters in strategic locations and currently houses more than 40,000 residents.

The hotel, to be named Hotel101-Cairo West, is planned to occupy a prime site in Hay Al Ashgar along Ahmed Zewail Road in 6th of October City, Giza. This strategic position is expected to offer guests connectivity via major arterial roads, including El Wahat Road and the Cairo Ring Road, with access to Sphinx International Airport and the wider Greater Cairo road network. The area has rapidly emerged as one of West Cairo's key growth districts, known for its modern infrastructure, improving transport links, and strong mix of residential, commercial, and tourism developments, while sitting within the broader catchment of the Giza Pyramids and the Grand Egyptian Museum.

Key Location Advantages:

* Prime Ahmed Zewail Road Position: Located along Ahmed Zewail Road with direct access to El Wahat Road and links to the Cairo Ring Road. Upon completion, guests are expected to benefit from road connectivity and proximity to Sphinx International Airport, providing access for both domestic and international travelers.

* Proximity to Major Attractions: Situated within the West Cairo corridor serving the Giza Pyramids and Grand Egyptian Museum. The site is expected to offer a balance of modern urban development and cultural tourism demand, with easy access to key attractions, residential communities, and commercial amenities across Greater Cairo.

When completed, Hotel101-Cairo West is expected to generate a total project value of approximately 5.465 billion Egyptian Pounds (US$102.09 million) and is expected to be completed by 2029, forming part of Hotel101 Global's global expansion strategy.

Hotel101-Cairo West is expected to offer 4-star amenities at affordable prices, including a ballroom, ample meeting spaces, and a conference center tailored for business events. Consistent with Hotel101's offerings across its locations globally, guests are expected to enjoy modern rooms, 24/7 reception, all-day dining, swimming pools, a full-size gym, a business center, children's playground, ample parking, luggage storage, and other amenities.

The development is subject to customary governmental, regulatory, corporate and other approvals.

About Hotel101 Global

Listed on Nasdaq (Ticker: HBNB) with a market capitalization of approximately US$1.1 billion as of October 16, 2026, Hotel101 is an asset-light, prop-tech hospitality platform pioneering a globally standardized "condotel" business model. Hotel101 aims to disrupt the global hotel and hospitality sector through its unique tech-enabled business model that positions it to generate revenues twice: first from the advance sale of individual hotel units during the construction phase; and second, from long-term recurring revenue derived from day-to-day hotel operations. The expansion of Hotel101 toward its long-term goal to operate in 100 countries globally is expected to be driven mainly by joint ventures and, in the future, license agreements with local developers in various countries worldwide.

The Hotel101 Global Group is advancing its global expansion plans toward its medium-term goal to be in 25 countries and its long-term goal of operating one million Hotel101 rooms in 100 countries globally.

Forward-Looking Statements

This document includes certain "forward-looking statements" within the meaning of securities laws of certain jurisdictions, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this document, including statements regarding the future financial position, business strategy, plans and objectives of management for future operations of Hotel101 Global Holdings Corp. ("HBNB") and its subsidiaries (the "HBNB Group"), are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "believe," "may," "estimate," "continue," "anticipate," "intend," "should," "plan," "set," "expect," "predict," "potential" or the negative of these terms or other similar expressions. Forward-looking statements include, without limitation, HBNB's expectations concerning anticipated sales revenue once fully sold and project value, the project location, expected number of rooms, expected project completion date and expansion goals, the outlook for the HBNB Group's business, productivity, plans and goals for future operational improvements and capital investments, operational performance, future market conditions or economic performance and developments in the capital and credit markets and expected future financial performance, as well as any information concerning possible or assumed future results of operations of the HBNB Group.

These forward-looking statements are based on the beliefs and assumptions of the management of HBNB. Although HBNB believes that such plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, HBNB cannot assure you that such plans, intentions or expectations will be achieved or realized. Forward-looking statements involve a number of risks, uncertainties and assumptions and actual results or events may differ materially from those projected or implied in those statements. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, the HBNB Group's ability to execute on its business model, potential business expansion opportunities in foreign countries and growth strategies, manage future growth, retain and expand customers' use of its hotel services and attract new customers, and source and maintain talent; risks relating to joint venture partners, including owners of pre-sold condotel units in Hotel101 hospitality projects, who may have interests different from and may take actions that adversely affect the HBNB Group; risks relating to project cost and completion; risks relating to the HBNB Group's sources of cash and cash resources; risks relating to offering deferred payment schemes, including the risk of customer default; the HBNB Group's ability to effectively compete in the highly competitive hospitality industry; any declines or disruptions in the travel and hospitality industries or economic downturn; applicable laws and regulations to real estate development and marketing activities and hotel operation and management activities in the jurisdictions where the HBNB Group has operations or intends to expand into; and other risks and uncertainties discussed in HBNB's annual report for the year ended December 31, 2025 on Form 20-F and under the heading "Risk Factors" in HBNB's registration statement on Form F-4 (File No.: 333-287130) and other documents to be filed by HBNB from time to time with the U.S. Securities and Exchange Commission.

The foregoing list of factors is not exhaustive. Should one or more of these risks or uncertainties materialize, or should any of HBNB's assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. There may be additional risks that are not presently known to HBNB or that HBNB currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements.

HBNB cautions you against placing undue reliance on forward-looking statements, which reflect current beliefs and are based on information currently available as of the date hereof. Forward-looking statements set forth herein speak only as of the date of this document. HBNB does not undertake any obligation to revise forward-looking statements to reflect future events, changes in circumstances, or changes in beliefs. In the event that any forward-looking statement is updated, no inference should be made that HBNB will make additional updates with respect to that statement, related matters or any other forward-looking statements.

Ondine Capital Announces First Close of Fund III to Drive AI and Semiconductor Innovation

Wed, 04 Nov 2026 07:36:00 +0700

Ondine Capital's newly appointed partner: Brian Yen

Source: Ondine Capital

TAIPEI, TAIWAN - Media OutReach Newswire - 3 November 2026 - Ondine Capital today announced the successful first close of its third USD-denominated VC fund. Ondine Capital Fund III has secured commitments from top-tier institutional and strategic limited partners, including several leading semiconductor enterprises in Taiwan.

Building on the firm's deep-rooted expertise in semiconductors and deep technology, Ondine Capital Fund III will invest across the full AI value chain-spanning AI foundation models, next-generation semiconductors, AI infrastructure, AI-native software, and physical AI applications.

Ondine Capital Fund III's early portfolio highlights include:

*Recursive Superintelligence: Founded by former Salesforce Chief Scientist Richard Socher and built by veteran researchers from OpenAI, Google, and Meta, the startup focuses on recursive self-improving AI systems. It recently raised $650 million at a $4 billion pre-money valuation led by Google Ventures, with participation from Nvidia and AMD.

*Bot Auto: Founded by Xiaodi Hou (former co-founder and CTO of TuSimple), this Houston-based physical AI startup specializes in autonomous freight transportation. Bot Auto recently partnered with Ryan Transportation to launch driverless freight operations along the Houston-Dallas corridor.

*Salience Labs: Founded by Vaysh Kewada and Johannes Feldmann, the company develops silicon-photonics optical switching technology for AI data centers. Partnering with Tower Semiconductor, Salience Labs recently closed a $125 million financing round led by Bullhound Capital, with strategic backing from AMD Ventures and Intel Capital.

Partner Appointment to Boost Global Ecosystem

Coinciding with the first close, Ondine Capital announced the appointment of Brian Yen as Partner, reinforcing the firm's global sourcing and founder network.

Prior to joining Ondine Capital, Brian Yen served as Principal and Head of the Taipei Office at Headline Asia, where he cultivated an extensive network across Japan, Taiwan, and Southeast Asia. His investment track record spans consumer technologies, agentic services, and physical AI, with notable investments including respond.io, forest inc., Braid, and iMotorbike. At Ondine Capital, Brian Yen will focus on backing early-stage founders building intelligent software and physical AI platforms.

"The convergence of AI and semiconductors is unleashing unprecedented opportunities across global tech," said Brian Yen. "As these technologies mature, we anticipate monumental value creation throughout the entire stack. Through Fund III, we look forward to empowering visionary founders who are shaping the future of computing and industry applications."

Ondine Capital continues to actively deploy capital and evaluate global investment opportunities in breakthrough, category-defining companies across the AI and semiconductor landscape.

About Ondine Capital

Ondine Capital is a premier venture capital firm focused on frontier technologies, including semiconductors, artificial intelligence, enterprise software, clean energy, and emerging technology platforms. The firm backs visionary founders from inception, providing strategic support and access to a robust global network of industrial partners, investors, and entrepreneurs.

The issuer is solely responsible for the content of this announcement.

Hashtags: #OndineCapital #RSI #BotAuto #SalienceLabs

https://www.ondinecap.com/

2026 Tropical Rainforest Ecosystem Partners Conference: Global Gathering to Protect Earth's Green Lungs

Wed, 04 Nov 2026 07:29:00 +0700

Photo: A Hainan Gibbon (Nomascus hainanus) photographed in the Bawangling Area of the National Park of Hainan Tropical Rainforest

Source: The Organizing Committee of 2026 Tropical Rainforest Ecosystem Partners Conference

HAIKOU, CHINA - Media OutReach Newswire - 3 November 2026 - From Nov. 18 to 22, 2026, a global gathering dedicated to protecting the Earth's "green lungs" will take place in Haikou, Hainan Province, China: the 2026 Tropical Rainforest Ecosystem Partners Conference.

From the vast Amazon rainforest to the dense forests of the Congo Basin and the diverse landscapes of the Malay Archipelago, representative rainforests from around the world will come together with the National Park of Hainan Tropical Rainforest for dialogue and exchange. Under the theme "Global Treasures ? Shared Future," the conference embodies humanity's shared commitment to protecting rainforests and pursuing sustainable development.

Tropical rainforests cover less than one-tenth of the Earth's land area, yet they are home to more than half of the world's plant and animal species. Hainan, China's only tropical island province, is home to the country's largest, most concentrated and best-preserved contiguous tropical rainforest on a continental island. Established in 2021, the National Park of Hainan Tropical Rainforest covers more than 4,269 square kilometers and protects over 95 percent of Hainan Island's primary forests. Its forest coverage rate remains stable at 95.9 percent, while both its water and air quality excellence rates stand at 100 percent.

Over the past five years, this rainforest has continued to witness remarkable ecological achievements. The Hainan gibbon population has grown to 44 individuals across seven groups, making it the only gibbon population in the world to have shown sustained growth.

In addition, 91 previously undocumented wild plant and animal species have been recorded in the park. An integrated space-air-ground ecological monitoring system now provides round-the-clock, comprehensive monitoring and protection of the rainforest ecosystem. The "Bawangling Model" for Hainan gibbon conservation has also been recognized by the International Union for Conservation of Nature (IUCN) as a global model for protecting rare species.

The conference will explore how forests can serve as reservoirs of water, sources of food, generators of economic value and carbon sinks. Two keynote forums and four parallel forums will be held, bringing together participants for in-depth discussions on key topics, including water conservation and aquatic ecological security, the sustainable use of forest food resources, ways to unlock the value of ecological products, and carbon management in rainforests. The discussions will foster exchanges of ideas and the sharing of experience.

The conference will also focus on Hainan's efforts to seek dual World Heritage recognition for its natural and cultural heritage. It will bring together global expertise to support the nomination of the Hainan Tropical Rainforest and the Traditional Settlement of Li Ethnic Group for inscription on the UNESCO World Heritage List as a mixed natural and cultural heritage property. The initiative will explore new approaches to rainforest governance that uphold ecological protection as a firm priority while bringing tangible benefits to local communities.

In addition to the conference sessions, a series of supporting events will be held. "Rainforest Night," a showcase of Hainan's intangible cultural heritage, will offer an immersive audiovisual experience showcasing the distinctive traditions of the Li and Miao ethnic groups. The "Hidden Realms ? Shared Life" Hainan Tropical Rainforest Photography Exhibition and the "Gifts of Nature" Ecological Products Market will showcase the rainforest's natural beauty and innovative ways of turning ecological resources into tangible benefits. Field expeditions into the Hainan Tropical Rainforest, media tours, and the public-interest initiative "Breathe Deep in the Rainforest ? Protect Our Shared Habitat" will take participants deep into the rainforest to experience the vitality of its ecosystems.

As the Hainan Free Trade Port approaches the first anniversary of the launch of island-wide special customs operations and the National Park of Hainan Tropical Rainforest marks its fifth anniversary, this conference will serve as China's green calling card to the world and provide a platform for international dialogue and cooperation on rainforest conservation.

The issuer is solely responsible for the content of this announcement.

Acronis Appoints HoJin Kim as Chief Revenue Officer

Wed, 04 Nov 2026 07:24:00 +0700

Acronis Appoints HoJin Kim as Chief Revenue Officer

Veteran channel executive brings more than 25 years of experience to accelerate global revenue growth and strengthen Acronis' MSP partner ecosystem

SCHAFFHAUSEN, Switzerland, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Acronis, a global provider of an AI-native cyber platform for MSPs and IT departments, today announced the appointment of HoJin Kim as Chief Revenue Officer (CRO).

In this role, HoJin will lead Acronis' global sales and go-to-market organization, with a focus on accelerating revenue growth, strengthening partner relationships, and expanding opportunities for managed service providers (MSPs) worldwide.

"HoJin's extensive channel expertise and proven ability to drive growth through partner ecosystems make him a strong addition to our leadership team," said Prakash Panjwani, CEO of Acronis. "As we continue to expand our global footprint and strengthen our position in the MSP market, his experience in scaling sales organizations, deepening partner engagement, and driving cybersecurity adoption will be instrumental in accelerating our next phase of growth."

HoJin brings more than 25 years of experience leading global and regional IT channel organizations, with deep expertise in cybersecurity, partner strategy, and driving growth through the channel. His appointment reinforces Acronis' commitment to its partner-first strategy and to building a scalable, high-performing global sales organization.

Most recently, HoJin served as Chief Revenue Officer at WatchGuard Technologies, where he led the company's global sales and channel organization. During his tenure, he focused on expanding the adoption of endpoint detection and response (EDR) and managed detection and response (MDR) services across MSPs, while driving network security sales and encouraging partners to leverage WatchGuard's Unified Security Platform.

"I'm excited to join Acronis and work with a company that puts partners and customers at the center of its strategy," said HoJin Kim. "Acronis has a compelling opportunity to help MSPs grow their businesses while enabling corporate customers to address increasingly complex cybersecurity and data protection challenges. I look forward to working with the global team to expand market opportunities, strengthen execution, and drive long-term growth across both our partner and corporate businesses."

Prior to WatchGuard, HoJin served as Chief Revenue Officer at The Channel Company, where he was responsible for driving revenue growth and executing the company's long-term strategy. He previously held senior global channel leadership positions at SonicWall, Samsung, and Hewlett Packard Enterprise, as well as regional partner management roles at Juniper Networks and IBM. Throughout his career, HoJin has developed and executed channel strategies designed to strengthen partner relationships, expand market reach, and deliver sustainable business growth.

About Acronis

Acronis is a leader in AI-native cyber protection, unifying data protection, cybersecurity, IT operations and hybrid infrastructure to deliver business continuity, security and compliance with less cost and complexity. More than 21,000 service providers trust Acronis to protect over 750,000 businesses in 150 countries. Acronis is headquartered in Schaffhausen, Switzerland. For more information, visit www.acronis.com.

Univar Solutions Completes Acquisition of Lavo Bulk Business in Canada

Wed, 04 Nov 2026 07:16:00 +0700

Transaction strengthens company's presence in Eastern Canada and expands complementary chemical solutions and capabilities for customers

DOWNERS GROVE, Ill., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Univar Solutions LLC ("Univar Solutions" or "the Company"), a leading global solutions provider to users of specialty ingredients and chemicals, today announced that it has completed the acquisition of the certain assets of KIK Consumer Products' Lavo Bulk business in Canada ("Lavo Bulk").

The acquisition strengthens Univar Solutions' presence in Eastern Canada and expands the complementary chemical solutions and capabilities the Company can provide to customers in the region.

"The addition of Lavo Bulk is a strong strategic fit with our business and our commitment to growing with key customers and critical suppliers in Canada," said Bob Craycraft, Chief Executive Officer, Chemical Distribution & Services for Univar Solutions. "We are pleased to welcome the Lavo Bulk team to Univar Solutions. Together, we look forward to building on their established expertise, relationships and capabilities while continuing to deliver the safe, reliable service our customers expect."

The Lavo Bulk leadership and sales team dedicated to the Lavo Bulk business have joined Univar Solutions, helping preserve established expertise, customer and supplier relationships, and knowledge of the business' operational and supply requirements.

"We see meaningful opportunities to build on the strength of the business and deepen our relationships with customers and supplier partners across the region," added Chris Halberg, Senior Regional Vice President, Canada and EMEA, Chemical Distribution & Services for Univar Solutions. "Our immediate focus is on a smooth transition, supporting our new colleagues and maintaining the high level of service customers have come to expect."

About Univar Solutions

Forward-Looking Statements

Forward-looking statements are subject to known and unknown risks and uncertainties, many of which may be beyond the Company's control, that could result in expectations not being realized or could otherwise materially and adversely affect the Company's business, financial condition, results of operations or cash flows. Although the forward-looking statements are based on what management believes to be reasonable assumptions, we caution you that the forward-looking information presented in this communication is not a guarantee of future events or results, and that actual events or results may differ materially from those made in or suggested by the forward-looking information contained in this communication.

Univar Solutions Merampungkan Akuisisi Bisnis Lavo Bulk di Kanada

Wed, 04 Nov 2026 07:12:00 +0700

Transaksi ini memperkuat kehadiran perusahaan di Kanada Timur serta memperluas solusi kimia pelengkap serta kapabilitas perusahaan bagi pelanggan

DOWNERS GROVE, Ill.,, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Univar Solutions LLC ("Univar Solutions" atau "Perusahaan"), penyedia solusi global terkemuka bagi pengguna bahan baku dan bahan kimia khusus, hari ini mengumumkan bahwa pihaknya telah merampungkan akuisisi atas sejumlah aset tertentu dari bisnis Lavo Bulk milik KIK Consumer Products di Kanada ("Lavo Bulk").

Akuisisi ini memperkuat kehadiran Univar Solutions di Kanada Timur serta memperluas solusi kimia pelengkap serta kapabilitas yang dapat ditawarkan Perusahaan kepada pelanggan di wilayah tersebut.

"Penambahan Lavo Bulk sangat selaras dengan strategi bisnis kami serta komitmen kami untuk terus bertumbuh bersama pelanggan utama dan pemasok penting di Kanada," ujar Bob Craycraft, Chief Executive Officer, divisi Chemical Distribution & Services di Univar Solutions. "Kami dengan senang hati menyambut bergabungnya tim Lavo Bulk ke Univar Solutions. Bersama-sama, kami berharap dapat terus mengembangkan keahlian, hubungan, dan kapabilitas yang telah mereka bangun, sekaligus terus memberikan layanan yang aman dan andal sesuai dengan yang diharapkan pelanggan kami."

Jajaran pimpinan dan tim penjualan Lavo Bulk yang secara khusus menangani bisnis Lavo Bulk telah bergabung dengan Univar Solutions. Langkah ini membantu mempertahankan keahlian yang telah dimiliki, hubungan dengan pelanggan dan pemasok, serta pengetahuan mengenai kebutuhan operasional dan pasokan bisnis tersebut.

"Kami melihat peluang besar untuk mengembangkan lebih lanjut keunggulan bisnis ini dan mempererat hubungan dengan pelanggan serta mitra pemasok di seluruh wilayah tersebut," tambah Chris Halberg, Senior Regional Vice President untuk Kanada dan EMEA pada divisi Chemical Distribution & Services di Univar Solutions. "Fokus utama kami saat ini adalah memastikan kelancaran proses transisi, yang mendukung rekan-rekan baru kami, serta mempertahankan standar layanan tinggi yang selama ini diharapkan pelanggan."

Tentang Univar Solutions

Univar Solutions merupakan distributor global terkemuka untuk bahan baku dan bahan kimia khusus, yang mewakili portofolio produk unggulan dari berbagai produsen terkemuka dunia. Didukung oleh salah satu armada transportasi milik sendiri dan tim penjualan teknis terbesar di industri, keahlian teknis tentang logistik yang tak tertandingi, pengetahuan mendalam tentang pasar dan regulasi, kemampuan pengembangan formulasi dan resep, serta perangkat digital terdepan, Perusahaan memiliki posisi kuat untuk menawarkan solusi khusus dan layanan bernilai tambah untuk berbagai pasar, industri, dan aplikasi.

Dalam mewujudkan tujuannya untuk membantu menjaga masyarakat tetap sehat, terpenuhi kebutuhan pangannya, bersih, dan aman, Univar Solutions berkomitmen membantu pelanggan dan pemasok berinovasi serta berfokus pada semangat Tumbuh Bersama. Pelajari lebih lanjut di univarsolutions.com.

Pernyataan Berwawasan ke Depan

Komunikasi ini memuat "pernyataan berwawasan ke depan" berdasarkan hukum yang berlaku tentang aspek keuangan dan operasional yang terkait dengan bisnis Perusahaan. Pernyataan berwawasan ke depan umumnya dapat dikenali dari penggunaan kata-kata seperti "meyakini," "memperkirakan," "mungkin," "akan," "seharusnya," "dapat," "berupaya," "bermaksud," "berencana," "mengestimasi," "mengantisipasi," atau istilah lainnya yang sebanding. Seluruh pernyataan berwawasan depan yang disampaikan dalam komunikasi ini dibatasi oleh pernyataan kehati-hatian ini.

Pernyataan berwawasan ke depan mengandung berbagai risiko dan ketidakpastian yang diketahui maupun tidak diketahui, yang sebagian besar mungkin berada di luar kendali Perusahaan, yang dapat menyebabkan ekspektasi tidak tercapai atau dapat berdampak secara signifikan dan merugikan terhadap bisnis, kondisi keuangan, hasil operasi, atau arus kas Perusahaan.

Meskipun pernyataan berwawasan ke depan didasarkan pada asumsi yang dianggap wajar oleh manajemen, kami mengingatkan bahwa informasi berwawasan ke depan yang disajikan dalam komunikasi ini bukan merupakan jaminan atas peristiwa atau hasil di masa mendatang, dan bahwa peristiwa atau hasil aktual dapat berbeda secara signifikan dari hal-hal yang dinyatakan secara tersurat maupun tersirat oleh informasi berwawasan ke depan yang dimuat dalam komunikasi ini.

Untuk informasi tambahan mengenai faktor-faktor yang dapat memengaruhi Perusahaan, silakan lihat laporan tahunan terbaru Perusahaan dan laporan keuangan lainnya, termasuk informasi yang tercantum dalam bagian berjudul "Faktor Risiko."

Setiap pernyataan berwawasan ke depan hanya mencerminkan pandangan Perusahaan pada tanggal komunikasi ini dan tidak boleh dianggap sebagai menggambarkan pandangan Perusahaan pada tanggal setelahnya dan Perusahaan tidak berkewajiban untuk memperbarui pernyataan berwawasan ke depan apa pun, kecuali sebagaimana diwajibkan oleh hukum.

Bitget Records $1.86 Trillion in Q3 Trading Volume, Expands Liquidity Across Crypto and TradFi

Wed, 04 Nov 2026 07:08:00 +0700

VICTORIA, Seychelles, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Bitget, the world's largest Universal Exchange (UEX), has released its Q3 2026 Transparency Report, recording $1.86 trillion in combined trading volume as trading activity grew across crypto derivatives, spot markets, and traditional financial products, supported by deeper liquidity and expanded cross-asset trading capabilities.

Trading activity scaled across every major category during the quarter, with combined monthly volume rising 21.2% from July to September. Crypto derivatives grew 31.5% to $409.19 billion, crypto spot volume rose 65.7%, and CFD trading expanded 39.7% to contribute $376.32 billion for the quarter, now the platform's largest non-crypto category.

That growth was supported by deepening liquidity. That direction took a concrete step forward with the launch of Bitget's Cross-Asset Unified Account (UTA), bringing more than 370 eligible assets, including 100+ tokenized US stocks, into a shared margin framework with collateral valuation ratios of up to 95%. The upgrade allows eligible tokenized equities to be used as collateral across different trading products, giving users more flexibility in managing their capital.

Bitget also expanded its AI-powered trading tools, extending GetAgent Playbook to tokenized US equities. Other developments included institutional pricing upgrades and the introduction of Cash Plus, a yield-generating stablecoin product.

"We're seeing more traders move between crypto, stocks and traditional assets, and that's why we are building a Universal Exchange," said Gracy Chen, CEO of Bitget. "Q3 showed strong growth, but it also reminded us that protecting our users must continue to remain our biggest priority as we expand."

Independent research also highlighted Bitget's liquidity performance. TokenInsight ranked Bitget first among nine exchanges for combined BTC and ETH futures depth within 0.05% of market price, recording $41.6 million in liquidity. CoinGecko identified Bitget among the leading exchanges for BTC and ETH spot liquidity. In tokenized equities, CryptoRank found Bitget's Reality recorded up to 58% lower simulated slippage on $50,000 orders than the next-lowest comparable venue, while DeFiLlama reported a median bid-ask spread of 0.83 basis points and the deepest top-of-book liquidity across five markets evaluated.

Following the September 24 security incident, Bitget implemented containment and recovery measures, with users account balances remaining unaffected. The company engaged Mandiant and SlowMist to support an independent investigation and replenished its Protection Fund to more than $300 million by September 30, ahead of its original commitment. Bitget also continued strengthening its security infrastructure by introducing a circuit breaker mechanism, passing an independent SlowMist assessment, and increasing its security budget, while maintaining a Proof of Reserves ratio above 110%.

About Bitget

Bitget is the world's largest Universal Exchange (UEX), serving over 125 million users and offering access to over 2M crypto tokens, 500+ tokenized stocks, ETFs, commodities, FX, and precious metals such as gold. The ecosystem is committed to helping users trade smarter with its AI agent, which co-pilots trade execution.

Bitget is driving crypto adoption through strategic partnerships such as MotoGP. Aligned with its global impact strategy, Bitget has joined hands with UNICEF to support blockchain education for 1.1 million people by 2027. Bitget currently leads in the tokenized TradFi market, providing the industry's lowest fees and highest liquidity across 150 regions worldwide.

Risk Warning: Digital asset prices are subject to fluctuation and may experience significant volatility. Investors are advised to only allocate funds they can afford to lose.

The value of any investment may be impacted, and there is a possibility that financial objectives may not be met, nor the principal investment recovered. Independent financial advice should always be sought, and personal financial experience and standing carefully considered.

Past performance is not a reliable indicator of future results. Bitget accepts no liability for any potential losses incurred. Nothing contained herein should be construed as financial advice. For further information, please refer to our Terms of Use.

GBA Science Forum 2026 Held Across Guangdong, Hong Kong, and Macao: Driving Collaborative Innovation to Build a Global Sci-Tech Hub

Wed, 04 Nov 2026 06:59:00 +0700

Scene from the Opening Ceremony of the 2026 Greater Bay Area Science Forum

Source: Guangdong Lingshan Forum Science Center

GUANGZHOU, CHINA - Media OutReach Newswire - 3 November 2026 - Co-hosted across Guangdong, Hong Kong, and Macao from October 31 to November 2, the 2026 Greater Bay Area (GBA) Science Forum took place with a strong focus on future industries and cutting-edge technologies.

Jointly guided by the Ministry of Science and Technology and the Chinese Academy of Sciences (CAS), this year's event highlights national strategic leadership to accelerate the implementation of key policies and technological breakthroughs in the region.

The forum features an opening ceremony, a main forum, 15 specialized sub-forums, and 10 signature events. While the opening ceremony and main forum were held on November 1 in Nansha, Guangzhou, parallel sessions are rolling out across Hong Kong, Shenzhen, Huizhou, Dongguan, and Yangjiang, demonstrating a deeply integrated and synergistic approach to the event across multiple cities.

The opening ceremony witnessed the release of new support measures for the GBA International Sci-Tech Innovation Center, jointly introduced by relevant state ministries and central authorities. A key highlight is the commitment to fortifying the region's original innovation capacity by supporting the development of a world-class cluster of major sci-tech infrastructures in the GBA. Furthermore, two national key R&D projects under the 15th Five-Year Plan, spearheaded by Guangdong Province, were officially launched: the "Advanced Biotherapeutic Technologies Project" and the "GBA International Sci-Tech Innovation Center Project."

The ceremony also featured the signing of the Guangdong-Hong Kong-Macao Collaborative Innovation Joint Funding Program, as well as major sci-tech cooperation agreements between CAS and Guangdong Province, marking another solid step in translating national strategic visions into concrete actions.

Since its inception in December 2021, the GBA Science Forum has been successfully held for five editions. It has evolved into a premier high-level exchange platform and a vital showcase for the matchmaking and achievements of the GBA International Sci-Tech Innovation Center.

This year's forum brought together four Nobel laureates, alongside distinguished academicians from home and abroad, young scientists, and leading tech entrepreneurs.

Together, they shared their latest research findings and visionary insights on critical topics, including cutting-edge scientific breakthroughs, future technological trends, and the deep integration of scientific and industrial innovation.

In recent years, the GBA International Sci-Tech Innovation Center has demonstrated robust innovation momentum and cultivated a thriving developmental environment. This vitality was globally recognized in September 2026, when the World Intellectual Property Organization (WIPO) published its Global Innovation Index 2026 Top 100 Science and Technology Clusters, with the "Shenzhen-Hong Kong-Guangzhou" cluster securing the number one spot globally once again.

The issuer is solely responsible for the content of this announcement.

Teva's Pivot to Growth Strategy Delivers 33% Growth Across Key Innovative Brands; Raises 2026 Outlook for AUSTEDO, AJOVY and UZEDY; Delivers Substantial Gross Margin Expansion

Tue, 03 Nov 2026 22:54:00 +0700

COMPANY STRENGTHENS NEUROSCIENCE LEADERSHIP WITH WELTRUZA LAUNCH AND STRATEGIC ADDITION OF BXCL-501

Q3 2026 revenues of $4.4 billion, a decrease of 2% year-over-year in both U.S. dollars and local currency terms, reflecting lower global generics revenues, primarily due to increased competition for lenalidomide capsules (a generic version of Revlimid) in the U.S. This decrease was partially offset by continued strong growth across Teva's key innovative brands.

Strong profitability: Gross profit margin was 55.5% in the third quarter of 2026, compared to 51.4% in the third quarter of 2025; non-GAAP gross profit margin increased to the highest quarterly level in the last decade, by 345 basis points to 58.7%, excluding the $500 million development milestone payments received for duvakitug (anti-TL1A) in Q4 2025; operating income was $714 million and non-GAAP operating income was $1,393 million; diluted earnings per share (EPS) was $0.20 and non-GAAP diluted EPS was $0.86; cash flow generated from operating activities was $241 million and free cash flow was approximately $0.5 billion.

Key innovative brands continued to drive Teva's portfolio transformation, collectively generating approximately $1.1 billion in revenues and growing 33% year-over-year in local currency:

AUSTEDO global revenues were $751 million, increasing 21% year-over-year in local currency. Teva is raising its 2026 revenue outlook to $2.55 billion-$2.65 billion, from $2.45 billion-$2.60 billion.

AJOVY global revenues were $269 million, increasing 61% year-over-year in local currency. Teva is raising its 2026 revenue outlook to $930 million-$960 million, from $850 million-$870 million.

UZEDY revenues were $85 million, increasing 96% year-over-year in local currency. Teva is raising its 2026 revenue outlook to $290 million?$310 million, from $270 million-$290 million.

Building the next wave of neuroscience growth: Teva received FDA approval for WELTRUZA in the U.S. in October 2026, marking a significant expansion for long-acting injectable schizophrenia treatment and highlighting Teva's established commercial capabilities and deep understanding of the patient journey. The Company continues to target LAI schizophrenia portfolio (UZEDY and WELTRUZA) with peak sales potential of $1.5 billion-$2.0 billion.

Expanding Teva's growth through strategic business development:

Acquired BXCL-501, from BioXcel Therapeutics Inc., which is under FDA review for potential at-home use for the acute treatment agitation associated with schizophrenia or bipolar I or II disorder in adults;

Deepened collaboration with Samsung Bioepis for the commercialization of two additional biosimilars, infliximab-abda, a biosimilar to Remicade? (infliximab), and etanercept-ykro, a biosimilar to Enbrel (etanercept), expanding the Company's burgeoning global pipeline and portfolio of biosimilars.

Generics and biosimilars remain an important foundation: global generics revenues decreased 16% year-over-year in local currency, primarily reflecting lower U.S. revenues from lenalidomide capsules (a generic version of Revlimid), partially offset by recently launched generic products and growth in biosimilars. Teva's biosimilars business continued to expand and is currently expected to exceed $0.8 billion in 2026 revenues, achieving our original 2027 revenue objective one year ahead of plan.

Innovative pipeline successes strengthen Teva's longer-term growth profile with the potential to launch at least one product per year over five years:

The U.S. FDA accepted the ecopipam New Drug Application (NDA) for review, advancing a potential first-in-class selective D1 receptor anti-agonist for Tourette syndrome in the pediatric population, with an action date expected in Q1 2027.

Teva reported positive Phase 2a results for anti-IL-15 (TEV-駰) in Celiac disease, and is targeting to begin Phase 2b in vitiligo in Q4 2026.

Teva discontinued its phase 2 Multiple System Atrophy (MSA) study of emrusolmin (TEV-饶), following an interim futility analysis that indicated low probability of the study meeting its primary efficacy endpoint if continued.

Financial strength, with continued value creation for shareholders: the return to an investment grade credit rating, refinancing of ~$4.9 billion in debt during Q3 2026, and the direct listing of Teva's ordinary shares on the New York Stock Exchange (NYSE); all reflect Teva's strong execution of its Pivot to Growth strategy, continued financial strength and long-term shareholder value creation.

Finalized Most-Favored-Nation (MFN) agreement with the U.S. Administration, including a prospective pricing commitment with respect to certain future innovative product launches.

Q3 2026 Highlights:

Revenues of $4.4 billion (-2% YoY)

GAAP diluted EPS of $0.20 (-47% YoY); non-GAAP diluted EPS of $0.86 (+10% YoY) includes $0.02 of acquired IPR&D charges

GAAP net income of $233 million; Adjusted EBITDA of $1.5 billion (+7% YoY)

Cash flow generated from operating activities of $241 million; Free cash flow of $495 million (-4% YoY)

GAAP gross profit margin of 55.5%; non-GAAP gross profit margin of 58.7%, an increase of 345 basis points year-over-year, the highest quarterly level in the last decade when excluding the $500 million development milestone payments received for duvakitug (anti-TL1A) in Q4 2025

2026 Business Outlook - Innovative brand revenues outlook increased, non-GAAP operating income outlook increased for underlying operational performance, offset by increased IPR&D*:

Revenues: $16.7-$17.0 billion

Non-GAAP operating income: $3.8-$3.9 billion; includes $0.87 billion of acquired IPR&D charges

Adjusted EBITDA: $4.23-$4.43 billion; includes $0.87 billion of acquired IPR&D charges

Non-GAAP diluted EPS: $1.92$-2.11; includes $0.71 of acquired IPR&D charges

Free cash flow: $2.1-$2.4 billion

AUSTEDO revenues: $2.55 billion-$2.65 billion

AJOVY revenues: $930 million-$960 million

UZEDY revenues: $290 million-$310 million

*IPR&D impact is presented due to uncertainty of the future occurrence and timing of these transactions

TEL AVIV, Israel, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended September 30, 2026.

Richard Francis, Teva's President and CEO, said: "Our strong third-quarter performance is another clear demonstration of Pivot to Growth in action and how far Teva has come. The FDA approval of WELTRUZA has further advanced our innovative portfolio, our recently announced biosimilars agreement with Samsung Bioepis has strengthened our generics powerhouse and our return to investment grade reflects the transformation of our financial position. Together, these achievements represent how we are delivering sustained innovative growth and translating that growth into greater profitability, with our three key innovative brands collectively growing 33% in local currency to approximately $1.1 billion year-over-year. This performance, together with continued margin expansion and cash flow generation, gives us the confidence to raise our 2026 revenue outlook for all three brands."

Mr. Francis added: "At the same time, we are continuously building the next phase of sustainable growth at Teva. The U.S. launch of WELTRUZA expands our schizophrenia franchise, while progress across ecopipam, anti-IL-15 and our broader late-stage pipeline supports our ambition to deliver at least five potential innovative launches over five years. Our return to investment grade and debt refinancing reflect our strengthened financial position."

Pivot to Growth Strategy

In the third quarter of 2026 and into October 2026, Teva continued to execute on the four pillars of its Pivot to Growth strategy:

Delivering on our growth engines

Teva's key innovative brands, AUSTEDO, AJOVY and UZEDY, collectively generated approximately $1.1 billion in revenues and grew 33% year-over-year in local currency. Strong performance across all three brands supports increased 2026 revenue outlooks of these products and continues to shift Teva's portfolio toward innovative medicines. The FDA approval and U.S. launch of WELTRUZA further expand Teva's long-acting injectable schizophrenia portfolio and builds on the commercial momentum established by UZEDY.

Stepping up innovation

Teva continued to advance a differentiated late-stage pipeline across neuroscience and immunology. The FDA accepted ecopipam's (EBS-101) NDA for review, positive Phase 2a results were reported for anti-IL-15 (TEV-駰) in Celiac disease, and the anti-IL-15 program is planned to advance into Phase 2b development in vitiligo later this year. Together with the acquisition of BXCL-501 (dexmetomidine sublingual film) from BioXcel Therapeutics, these milestones expand Teva's capabilities in areas of significant unmet need and support its ambition to deliver a sustained cadence of potential launches.

Sustaining our generics powerhouse

Teva continues to strengthen its global generics business through an increased focus on complex generics and biosimilars. While global generics revenues declined primarily due to lower revenues of lenalidomide capsules (a generic version of Revlimid?) in the U.S., revenues from biosimilars continued to expand. Teva currently expects more than $0.8 billion in biosimilars revenues in 2026, reaching its original 2027 revenue objective one year early, with further portfolio expansion supported by new collaborations, including the recently announced agreement with Samsung Bioepis.

Focusing our business

Teva continued to transform and modernize its business through the Teva Transformation programs, which combined with innovative product growth potential, is expected to support the Company's objective of achieving a 30% non-GAAP operating income margin and approximately $700 million of net savings, by 2027 including -two-thirds expected to be realized in 2026. At the same time, Teva continued to maintain disciplined capital allocation and strengthen its financial profile. During Q3 2026, Moody's and S&P upgraded Teva to investment grade, following Fitch's earlier upgrade; and Teva refinanced ~$4.9 billion of debt. All these reflect Teva's goal to achieve two times debt leverage by the end of 2027.

Third Quarter 2026 Consolidated Results

Revenues in the third quarter of 2026 were $4,395 million, a decrease of 2% in both U.S. dollars and local currency terms compared to the third quarter of 2025. This decrease was mainly due to lower revenues from generic products, primarily lenalidomide capsules (a generic version of Revlimid?) in our U.S. segment, partially offset by higher revenues from our key innovative products, primarily AUSTEDO, AJOVY and UZEDY.

Exchange rate movements in the third quarter of 2026, net of hedging effects, positively impacted revenues by $5 million, compared to the third quarter of 2025.

Gross profit in the third quarter of 2026 was $2,440 million, an increase of 6% compared to $2,304 million in the third quarter of 2025. Gross profit margin was 55.5% in the third quarter of 2026, compared to 51.4% in the third quarter of 2025. Non-GAAP gross profit was $2,580 million in the third quarter of 2026, an increase of 4% compared to $2,475 million in the third quarter of 2025. Non-GAAP gross profit margin was 58.7% in the third quarter of 2026, compared to 55.3% in the third quarter of 2025. The increase in both gross profit margin and non-GAAP gross profit margin was mainly due to a favorable mix of products, primarily higher revenues from our key innovative products, largely AUSTEDO, partially offset by lower revenues from generic products, primarily lenalidomide capsules (a generic version of Revlimid).

Research and Development (R&D) expenses, net in the third quarter of 2026, were $297 million, an increase of 16% compared to $256 million in the third quarter of 2025. This increase was mainly due to higher expenses in our immunology and neuroscience projects, as well as in our biosimilars pipeline. Our R&D expenses, net in the third quarters of 2026 and 2025, were also impacted by reimbursements and cost sharing from our strategic partnerships and collaborations entered into in recent years.

Selling and Marketing (S&M) expenses in the third quarter of 2026, were $709 million, an increase of 8% compared to the third quarter of 2025. This increase was mainly due to promotional activities related to our key innovative products, primarily AUSTEDO, and other innovative product launch preparation activities in our U.S. segment.

General and Administrative (G&A) expenses in the third quarter of 2026 were $298 million, a decrease of 6% compared to the third quarter of 2025.

Other Income in the third quarter of 2026 was $68 million, compared to other loss of $7 million in the third quarter of 2025, mainly related to a capital gain from the sale of a property in Europe.

Operating Income was $714 million in the third quarter of 2026, compared to an operating income of $882 million in the third quarter of 2025. Operating Income as a percentage of revenues was 16.2% in the third quarter of 2026, compared to 19.7% in the third quarter of 2025. This decrease was mainly due to higher tangible asset impairments and higher legal settlements and loss contingencies, partially offset by an increase in gross profit. Non-GAAP operating income in the third quarter of 2026 was $1,393 million representing a non-GAAP operating margin of 31.7% compared to $1,294 million representing 28.9%, respectively, in the third quarter of 2025. This increase in non-GAAP operating margin in the third quarter of 2026 was mainly due to higher gross profit margin as described above.

Exchange rate movements in the third quarter of 2026, net of hedging effects, had a negative impact of $2 million on our operating income and non-GAAP operating income compared to the third quarter of 2025.

Financial expenses, net in the third quarter of 2026, were $414 million, mainly comprised of a loss of $224 million on extinguishment of debt and net interest expenses of $174 million. In the third quarter of 2025, financial expenses, net were $237 million, mainly comprised of net interest expenses of $209 million.

In the third quarter of 2026, we recognized a tax expense of $66 million on pre-tax income of $300 million. In the third quarter of 2025, we recognized a tax expense of $214 million on pre-tax income of $646 million.

Our tax rate in the third quarter of 2026 was 22.1%, compared to 33.1% in the third quarter of 2025. Non-GAAP tax rate in the third quarter of 2026 was 16.5%, compared to 14.7% in the third quarter of 2025. Our tax rate and non-GAAP tax rate in the third quarter of 2026 were mainly affected by the generation of profits in various jurisdictions in which tax rates are different than the Israeli tax rate and other infrequent or non-recurring items. Our tax rate and non-GAAP tax rate in the third quarter of 2025 were mainly affected by changes in deferred tax balances due to statutory tax rate changes and interest and inflation adjustments related to the agreement with the Israeli Tax Authorities.

Considering the above, we expect our annual non-GAAP tax rate for 2026 to be between 20%-23%, higher than our non-GAAP tax rate for 2025, which was 15.8%.

Net income attributable to Teva and diluted earnings per share in the third quarter of 2026 were $233 million and $0.20, respectively, compared to net income attributable to Teva and diluted earnings per share of $433 million and $0.37, respectively, in the third quarter of 2025. This decrease was mainly due to lower operating income, as discussed above. Non-GAAP net income attributable to Teva and non-GAAP diluted earnings per share in the third quarter of 2026 were $1,013 million and $0.86, respectively, compared to $910 million and $0.78, respectively, in the third quarter of 2025.

Adjusted EBITDA was $1,496 million in the third quarter of 2026, an increase of 7%, compared to $1,394 million in the third quarter of 2025.

As of September 30, 2026 and 2025, the fully diluted share count for purposes of calculating our market capitalization was approximately 1,195 million shares and 1,184 million shares, respectively.

Non-GAAP information: non-GAAP adjustments in the third quarter of 2026 were $780 million. Non-GAAP net income attributable to Teva and non-GAAP diluted EPS for the third quarter of 2026 were adjusted to exclude the following items:

Amortization of purchased intangible assets of $139 million, of which $129 million is included in cost of sales and the remaining $9 million in S&M expenses;

Legal settlements and loss contingencies of $201 million;

Restructuring expenses of $58 million;

Impairment of long-lived assets of $228 million;

Contingent consideration expenses of $2 million;

Equity compensation expenses of $38 million;

Financial expenses of $235 million;

Other non-GAAP items of $14 million; and

Corresponding tax effects and unusual tax items of $134 million.

We believe that excluding such items facilitates investors' understanding of our business including underlying trends, thereby improving the comparability of our business performance results between reporting periods.

For a reconciliation of the U.S. GAAP results to the adjusted non-GAAP figures and for additional information, see the tables below and the information included under "Non-GAAP Financial Measures." Investors should consider non-GAAP financial measures in addition to, and not as replacement for, or superior to, measures of financial performance prepared in accordance with GAAP.

Cash flow generated from operating activities during the third quarter of 2026 was $241 million compared to $369 million in the third quarter of 2025. The lower cash flow generated from operating activities in the third quarter of 2026 resulted mainly from the timing of sales and collections, partially offset by lower legal settlement payments.

During the third quarter of 2026, we generated free cash flow of $495 million, which we define as comprising: $241 million in cash flow generated from operating activities, $327 million in beneficial interest collected in exchange for securitized accounts receivables (under our EU securitization program) and $47 million of proceeds from the sale of businesses and long-lived assets, partially offset by $120 million in cash used for capital investments. During the third quarter of 2025, we generated free cash flow of $515 million, which we define as comprising $369 million in cash flow generated from operating activities, $274 million in beneficial interest collected in exchange for securitized accounts receivables (under our EU securitization program) and $8 million of proceeds from the sale of businesses and long-lived assets, partially offset by $136 million in cash used for capital investments. The decrease in the third quarter of 2026 resulted mainly from lower cash flow generated from operating activities, as discussed above, partially offset by higher proceeds from the sale of businesses and long-lived assets.

As of September 30, 2026, our debt was $16,718 million, compared to $16,807 million as of December 31, 2025. This decrease was mainly due to $256 million of exchange rate fluctuations. In addition, during the third quarter of 2026, we consummated an early redemption of $4,678 million in aggregate principal amount of senior notes and concurrently, issued $4,837 million of new senior notes, net of discount and issuance costs. The portion of total debt classified as short-term as of September 30, 2026 was 24% compared to 11% as of December 31, 2025. Our financial leverage, which is the ratio between our debt and the sum of our debt and equity, was 68% as of September 30, 2026 and December 31, 2025. Our average debt maturity was approximately 6.3 years as of September 30, 2026, compared to 5.6 years as of December 31, 2025.

Segment Results for the third quarter of 2026

United States Segment

In alignment with our Pivot to Growth strategy, commencing January 1, 2026, Anda is no longer reported under our United States segment. This shift allows the United States segment to continue to manage its entire product portfolio in the region, while strengthening focus on its biopharmaceutical business, growth engines and innovation. As a result, from that date, Anda is reported as part of the Company's Other Activities. Prior period amounts were recast to reflect this change.

The following table presents revenues, expenses and profit for our United States segment for the three months ended September 30, 2026 and 2025:

Three months ended September 30,
	2026			2025
	(U.S. $ in millions / % of Segment Revenues)
Revenues	$	1,870	100 %	$	2,090	100 %
Cost of sales	467		25.0 %	645		30.9 %
Gross profit	1,403		75.0 %	1,446		69.1 %
R&D expenses	196		10.5 %	161		7.7 %
S&M expenses	306		16.4 %	248		11.8 %
G&A expenses	109		5.9 %	113		5.4 %
Other	?		?	(3)		?
Segment profit*	$	791	42.3 %	$	927	44.3 %

_______________________
* Segment profit does not include amortization and certain other items.
? Represents an amount less than $0.5 million or 0.5% as applicable.

Revenues from our United States segment in the third quarter of 2026 were $1,870 million, a decrease of 11% compared to the third quarter of 2025, mainly due to lower revenues from generic products, primarily lenalidomide capsules (a generic version of Revlimid?), partially offset by higher revenues from our key innovative products, primarily AUSTEDO, AJOVY, and UZEDY.

Revenues by Major Products and Activities

The following table presents revenues for our United States segment by major products and activities for the three months ended September 30, 2026 and 2025:

	Three months ended				Percentage
	September 30,				Change
	2026		2025		2026-2025
	(U.S.$ in millions)

Generic products (including biosimilars)	$	718	$	1,175	(39)%
AJOVY	138		73		88%
AUSTEDO	727		601		21%
BENDEKA and TREANDA	30		35		(15)%
COPAXONE	58		62		(8)%
UZEDY	85		43		96%
Other	114		101		13%
Total	$	1,870	$	2,090	(11)%

Generic products (including biosimilar products) revenues in our United States segment in the third quarter of 2026 were $718 million, a decrease of 39% compared to the third quarter of 2025. This decrease was mainly driven by lower revenues from lenalidomide capsules (a generic version of Revlimid) due to increased generic competition in the U.S., partially offset by higher revenues from our portfolio of biosimilar products and from recently launched generic products.

Among the most significant generic products we sold in the United States in the third quarter of 2026 were epinephrine injectable solution (a generic equivalent of EpiPen and EpiPen Jr), TRUXIMA (a biosimilar to Rituxan), and SIMLANDI (a biosimilar to Humira). In the third quarter of 2026, our total prescriptions were approximately 227 million (based on trailing twelve months), representing 5.8% of total U.S. generic prescriptions, compared to approximately 261 million (based on trailing twelve months), representing 6.7% of total U.S. generic prescriptions in the third quarter of 2025, all according to IQVIA data.

On September 28, 2026, we announced that the FDA approved DEGEVMA (denosumab-adet) as a biosimilar to Xgeva (denosumab). DEGEVMA is indicated for the prevention of bone complications in adults with advanced cancer that has spread to the bone, for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone, and for the treatment of hypercalcemia of malignancy.

AJOVY revenues in our United States segment in the third quarter of 2026 were $138 million, an increase of 88% compared to the third quarter of 2025, mainly due to a reduction in sales allowance as well as growth in volume. In the third quarter of 2026, AJOVY's exit market share in the United States in terms of total number of prescriptions was 32.8% out of the subcutaneous injectable anti-CGRP class, compared to 32.2% in the third quarter of 2025.

AUSTEDO revenues (which include AUSTEDO XR) in our United States segment in the third quarter of 2026 were $727 million, an increase of 21%, compared to the third quarter of 2025. This increase was mainly due to growth in volume and a favorable business mix including improved net-price realization.

AUSTEDO XR (deutetrabenazine) extended-release tablets was approved by the FDA on February 17, 2023 in three doses of 6, 12 and 24 mg, and became commercially available in the U.S. in May 2023. The FDA approved AUSTEDO XR as a one pill, once-daily treatment option in doses of 30, 36, 42, and 48 mg in May 2024 and in 18 mg in July 2024. AUSTEDO XR is a once-daily formulation indicated in adults for tardive dyskinesia and chorea associated with Huntington's disease, which is additional to the twice-daily AUSTEDO.

UZEDY (risperidone) extended-release injectable suspension revenues in our United States segment in the third quarter of 2026 were $85 million, an increase of 96% compared to the third quarter of 2025, mainly due to growth in volume.

On October 9, 2026, we announced that the FDA approved WELTRUZA (olanzapine) for extended-release injectable suspension, a new once-monthly, subcutaneous long-acting injectable (LAI) for the treatment of schizophrenia in adults. WELTRUZA is expected to become available in the U.S. in the coming weeks, in three different strengths (318 mg, 425 mg, 531 mg). In May 2026, the European Medicines Agency accepted Teva's Marketing Authorization Application for olanzapine LAI (TEV-'749). WELTRUZA is protected in the U.S. by four Orange Book listed patents expiring between 2033 and 2044, and in Europe by five granted patents expiring between 2031 and 2044.

BENDEKA and TREANDA combined revenues in our United States segment in the third quarter of 2026 were $30 million, a decrease of 15% compared to the third quarter of 2025, mainly due to competition from alternative therapies, as well as from branded and generic bendamustine products.

COPAXONE revenues in our United States segment in the third quarter of 2026 were $58 million, a decrease of 8% compared to the third quarter of 2025.

United States Gross Profit

Gross profit from our United States segment in the third quarter of 2026 was $1,403 million, a decrease of 3%, compared to the third quarter of 2025.

Gross profit margin for our United States segment in the third quarter of 2026 increased to 75.0%, compared to 69.1% in the third quarter of 2025. This increase was mainly due to a favorable mix of products, primarily higher revenues from our key innovative products, largely AUSTEDO, partially offset by lower revenues from lenalidomide capsules (a generic version of Revlimid?).

United States Profit

Profit from our United States segment consists of revenues less cost of sales, R&D expenses, S&M expenses, G&A expenses and other expenses (income) related to this segment. Segment profit does not include amortization and certain other items.

Profit from our United States segment in the third quarter of 2026 was $791 million, a decrease of 15% compared to $927 million in the third quarter of 2025. This decrease was mainly due to higher S&M expenses and lower gross profit, as discussed above.

Europe Segment

Our Europe segment includes the European Union, the United Kingdom and certain other European countries.

The following table presents revenues, expenses and profit for our Europe segment for the three months ended September 30, 2026 and 2025:

Three months ended September 30,
	2026			2025
	(U.S. $ in millions / % of Segment Revenues)
Revenues	$	1,319	100 %	$	1,235	100 %
Cost of sales	562		42.6 %	570		46.1 %
Gross profit	757		57.4 %	665		53.9 %
R&D expenses	62		4.7 %	62		5.0 %
S&M expenses	211		16.0 %	225		18.2 %
G&A expenses	64		4.8 %	75		6.1 %
Other	?		?	?		?
Segment profit*	$	420	31.8 %	$	303	24.5 %

_______________________
* Segment profit does not include amortization and certain other items.
? Represents an amount less than $0.5 million or 0.5%, as applicable.

Revenues from our Europe segment in the third quarter of 2026 were $1,319 million, an increase of 7% in both U.S. dollars and local currency terms, compared to the third quarter of 2025. This increase was mainly due to higher revenues from generic products, higher proceeds from the sale of certain product rights, and higher revenues from AJOVY.

In the third quarter of 2026, revenues were negatively impacted by exchange rate fluctuations of $7 million, net of hedging effects, compared to the third quarter of 2025. Revenues in the third quarter of 2026 included $17 million from a positive hedging impact, compared to $6 million in the third quarter of 2025, which are included in "Other" in the table below.

Revenues by Major Products and Activities

The following table presents revenues for our Europe segment by major products and activities for the three months ended September 30, 2026 and 2025:

	Three months ended				Percentage
	September 30,				Change
	2026		2025		2026-2025
	(U.S.$ in millions)

Generic products (including OTC and biosimilars)	$	1,033	$	982	5%
AJOVY	84		66		28%
COPAXONE	38		44		(12)%
Respiratory products	54		52		3%
Other*	111		91		21%
Total	$	1,319	$	1,235	7%

_______________________
* Other revenues in the third quarters of 2026 and 2025 include the sale of certain product rights.

Generic products revenues (including OTC and biosimilar products) in our Europe segment in the third quarter of 2026 were $1,033 million, an increase of 5% compared to the third quarter of 2025. In local currency terms, revenues increased by 7%, mainly due to higher sales of generic and OTC products, including from recently launched products.

AJOVY revenues in our Europe segment in the third quarter of 2026 were $84 million, an increase of 28% compared to the third quarter of 2025. In local currency terms revenues increased by 29% mainly due to higher volumes.

COPAXONE revenues in our Europe segment in the third quarter of 2026 were $38 million, a decrease of 12% compared to the third quarter of 2025. In local currency terms revenues decreased by 11%, mainly due to price reductions and lower volumes resulting from the availability of alternative therapies.

Respiratory products revenues in our Europe segment in the third quarter of 2026 were $54 million, an increase of 3% compared to the third quarter of 2025. In local currency terms, revenues increased by 4%, mainly due to higher volumes as a result of increased supply.

Europe Gross Profit

Gross profit from our Europe segment in the third quarter of 2026 was $757 million, an increase of 14% compared to the third quarter of 2025. Gross profit margin for our Europe segment in the third quarter of 2026 increased to 57.4%, compared to 53.9% in the third quarter of 2025. This increase was mainly due to higher proceeds from the sale of certain product rights and a positive impact from hedging activities.

Europe Profit

Profit from our Europe segment consists of revenues less cost of sales, R&D expenses, S&M expenses, G&A expenses and other expenses (income) related to this segment. Segment profit does not include amortization and certain other items.

Profit from our Europe segment in the third quarter of 2026 was $420 million, an increase of 39%, compared to the third quarter of 2025. This increase was mainly due to higher gross profit, as discussed above.

International Markets Segment

Our International Markets segment includes all countries in which we operate other than the United States and the countries included in our Europe segment. The International Markets segment covers a substantial portion of the global pharmaceutical industry, including more than 35 countries. The countries in our International Markets segment include highly regulated, mainly generic markets, such as Canada and Israel, and branded generics-oriented markets, such as Russia and certain Latin America markets.

As of the date of this Quarterly Report on Form 10-Q, sustained conflict between Russia and Ukraine and disruption in the region is ongoing. Russia and Ukraine markets are included in our International Markets segment results and we have no manufacturing or R&D facilities in these markets. In September 2026, a warehouse that we share with other pharmaceutical companies in Ukraine was damaged, and, as of the date of this Quarterly Report on Form 10-Q, operations at this warehouse resumed. The impact of this conflict on our International Markets segment in the third quarter of 2026 was immaterial.

The following table presents revenues, expenses and profit for our International Markets segment for the three months ended September 30, 2026 and 2025:

	Three months ended September 30,
	2026			2025
	(U.S. $ in millions / % of Segment Revenues)

Revenues	$	592	100 %	$	557	100 %
Cost of sales	276		46.7 %	280		50.2 %
Gross profit	316		53.3 %	278		49.8 %
R&D expenses	31		5.3 %	26		4.6 %
S&M expenses	125		21.2 %	122		21.9 %
G&A expenses	34		5.7 %	36		6.4 %
Other	?		?	?		?
Segment profit*	$	125	21.1 %	$	95	17.0 %

_______________________
* Segment profit does not include amortization and certain other items.
? Represents an amount less than $0.5 million or 0.5%, as applicable.

Revenues from our International Markets segment in the third quarter of 2026 were $592 million, an increase of 6% compared to the third quarter of 2025. In local currency terms, revenues increased by 4% compared to the third quarter of 2025, mainly due to higher revenues from our key innovative products AJOVY and AUSTEDO.

In the third quarter of 2026, revenues were positively impacted by exchange rate fluctuations of $13 million, including hedging effects, compared to the third quarter of 2025. Revenues in the third quarter of 2026 included $7 million from a positive hedging impact, compared to $2 million in the third quarter of 2025, which are included in "Other" in the table below.

Revenues by Major Products and Activities

The following table presents revenues for our International Markets segment by major products and activities for the three months ended September 30, 2026 and 2025:

	Three months ended				Percentage
	September 30,				Change
	2026		2025		2026-2025
	(U.S.$ in millions)

Generic products (including OTC and biosimilars)	$	407	$	421	(3)%
AJOVY	48		30		61%
AUSTEDO	24		17		42%
COPAXONE	8		8		8%
Other*	105		82		28%
Total	$	592	$	557	6%

_______________________
*Other revenues in the third quarters of 2026 and 2025 include the sale of certain product rights.

Generic products revenues (including OTC and biosimilar products) in our International Markets segment in the third quarter of 2026 were $407 million, a decrease of 3% compared to the third quarter of 2025. In local currency terms, revenues decreased by 4%, mainly due to lower revenues from generic and OTC products in certain markets including Ukraine.

AJOVY revenues in our International Markets segment in the third quarter of 2026 were $48 million, an increase of 61% in both U.S. dollars and local currency terms compared to the third quarter of 2025. This increase was mainly due to growth in multiple markets. In April 2026, we announced a strategic partnership for the marketing and distribution of AJOVY in China with Nuerogen (Zhuhai) Pharmaceutical Company Ltd.

AUSTEDO revenues in our International Markets segment in the third quarter of 2026 were $24 million, an increase of 42% compared to the third quarter of 2025. In local currency terms, revenue increased by 34% compared to the third quarter of 2025, mainly due to growth in China.

COPAXONE revenues in our International Markets segment in the third quarter of 2026 were $8 million, an increase of 8% compared to the third quarter of 2025.

International Markets Gross Profit

Gross profit from our International Markets segment in the third quarter of 2026 was $316 million, an increase of 14% compared to the third quarter of 2025.

Gross profit margin for our International Markets segment in the third quarter of 2026 increased to 53.3%, compared to 49.8% in the third quarter of 2025. This increase was mainly due to a favorable mix of products, primarily attributed to higher revenues from AJOVY and AUSTEDO, partially offset by lower revenues from generic products, as discussed above.

International Markets Profit

Profit from our International Markets segment consists of revenues less cost of sales, R&D expenses, S&M expenses, G&A expenses and other expenses (income) related to this segment. Segment profit does not include amortization and certain other items.

Profit from our International Markets segment in the third quarter of 2026 was $125 million, an increase of 32%, compared to the third quarter of 2025. This increase was mainly due to higher gross profit, as discussed above.

Other Activities

We have other sources of revenues, primarily our distribution business in the United States to third parties through Anda, the sale of APIs to third parties, an out-licensing platform offering a portfolio of products to other pharmaceutical companies through our affiliate Medis, and certain contract manufacturing services. Our Other Activities are not included in our United States, Europe or International Markets segments described above.

In alignment with our Pivot to Growth strategy, commencing January 1, 2026, Anda is no longer reported under our United States segment. As a result, from that date, Anda is reported as part of our Other Activities. Prior period amounts were recast to reflect this change.

In 2024, we announced that we intend to divest our API business (including its R&D, manufacturing and commercial activities) through a sale. The intention to divest is in alignment with our Pivot to Growth strategy, and Teva is conducting a sales process for this matter. However, there can be no assurance regarding the ultimate timing or structure of a potential divestiture or that a divestiture will be completed at all.

Our revenues from Other Activities in the third quarter of 2026 were $613 million, an increase of 3% in both U.S. dollars and local currency terms, compared to the third quarter of 2025.

Anda revenues from third-party products in the third quarter of 2026 were $401 million, an increase of 2%, compared to the third quarter of 2025, mainly due to higher volumes. Anda, our distribution business in the United States, operates independently and distributes generic and innovative medicines and OTC pharmaceutical products from various manufacturers to independent retail pharmacies, pharmacy retail chains, hospitals and physician offices in the United States. Anda competes in the distribution market by maintaining a broad portfolio of products, competitive pricing and delivery throughout the United States.

API sales to third parties in the third quarter of 2026 were $115 million, a decrease of 8% in both U.S. dollars and local currency terms, compared to the third quarter of 2025. This decrease was mainly due to lower demand resulting from market dynamics and temporary supply challenges.

Revenues from additional other activities, mainly from Medis and certain contract manufacturing services, were $98 million in the third quarter of 2026, an increase of 21% in U.S. dollars, or 23% in local currency terms compared to the third quarter of 2025, mainly due to higher demand.

2026 Financial Outlook

$ billions, except diluted EPS or as noted	Prior Guidance	Updated Guidance	Key Assumptions
Revenues	$16.5 - $16.85	$16.7 - $17.0	Assume growth in innovative products
AUSTEDO ($m)	2,450 - 2,600	2,550 - 2,650
AJOVY ($m)	850 - 870	930 - 960
UZEDY ($m)	270 - 290	290 - 310
Operating Income*	3.8 - 4.0	3.8 - 3.9	Increase of $0.05B before updating guidance for $0.1B impact of acquired IPR&D charge
Adjusted EBITDA*	4.23 - 4.53	4.23 - 4.43
Finance Expenses*	~$0.8	~$0.8
Tax Rate*	20% - 23%	20% - 23%
Diluted EPS* ($)	1.91 - 2.11	1.92 - 2.11	Increase of $0.08 at midpoint before updating guidance for $0.07 impact of acquired IPR&D charge
Free Cash Flow*	2.0 - 2.4	2.1 - 2.4
CAPEX	0.5	0.5
Foreign Exchange	Volatile swings in FX can negatively impact revenue and income

Financial guidance only assumes business development transactions closed as of November 3, 2026.

*Certain items above are non-GAAP financial measures. For more information, see "Non-GAAP Financial Measures" below. Free Cash Flow includes cash flow generated from operating activities net of capital expenditures and deferred purchase price cash component collected for securitized trade receivables.

Conference Call

Teva will host a conference call and live webcast along with a slide presentation on Tuesday, November 3, 2026 at 8:00 a.m. ET to discuss its third quarter 2026 financial results and overall business environment.

A question & answer session will follow.

In order to participate, please register in advance here to obtain a local or toll‐free phone number and your personal pin.

A live webcast of the call will be available on Teva's website at: www.tevapharm.com

Following the conclusion of the call, a replay of the webcast will be available within 24 hours on Teva's website.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva's commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients' needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.

Some amounts in this press release may not add up due to rounding. All percentages have been calculated using unrounded amounts.

Non-GAAP Financial Measures

This press release contains certain financial information that differs from what is reported under accounting principles generally accepted in the United States ("GAAP"). These non-GAAP financial measures, including, but not limited to, non-GAAP operating income, non-GAAP operating margin, non-GAAP gross profit, non-GAAP gross profit margin, Adjusted EBITDA, free cash flow, non-GAAP tax rate, non-GAAP net income (loss) attributable to Teva and non-GAAP diluted EPS, are presented in order to facilitate investors' understanding of our business. We utilize certain non-GAAP financial measures to evaluate performance in conjunction with other performance metrics. The following are examples of how we utilize the non-GAAP measures: our management and board of directors use the non-GAAP measures to evaluate our operational performance and, to compare our results against work plans and budgets, and ultimately to evaluate the performance of management; our annual budgets are prepared on a non-GAAP basis; and senior management's annual compensation is derived, in part, using these non-GAAP measures. See the attached tables for a reconciliation of the GAAP results to the adjusted non-GAAP measures. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. We are not providing the most comparable forward-looking GAAP measures for non-GAAP metrics included in our financial outlook or a quantitative reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP measures because we are unable to predict with reasonable certainty the ultimate outcome of certain significant items including, but not limited to, the amortization of purchased intangible assets, legal settlements and loss contingencies, impairment of long-lived assets and goodwill impairment, without unreasonable effort. These items are uncertain, depend on various factors, and could be material to our results computed in accordance with GAAP.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as "should," "will", "expect," "aim", "anticipate," "estimate," "target," "may," "project," "guidance," "intend," "plan," "believe", "outlook", "transition" and other words and terms of similar meaning and expression in connection with any discussion of future operating financial performance or development. Important factors that could cause or contribute to such differences include risks relating to:

our ability to successfully compete in the marketplace, including: that we are substantially dependent on our generic products; concentration of our customer base and commercial alliances among our customers; competition faced by our generic medicines from other pharmaceutical companies; changes in regulatory policy that may result in costs and delays; delays in launches of new generic products; our ability to develop and commercialize additional pharmaceutical products in a timely manner; intense competition for our innovative medicines; our ability to achieve expected results from investments in our product pipeline; our ability to successfully execute on our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline, to profitably commercialize our innovative medicines and biosimilar portfolio, whether organically or through business development, and to sustain and focus our portfolio of generics medicines, and to execute on our organizational transformation and to achieve expected cost savings; and the effectiveness of our patents and other measures to protect our intellectual property rights;
our significant indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments; and our potential need to raise additional funds in the future, which may not be available on acceptable terms or at all;
our business and operations in general, including: the impact of global geopolitical, economic conditions and other macroeconomic developments and the governmental and societal responses thereto, and our exposure to changes in international trade policies, including the imposition of tariffs in the jurisdictions in which we operate and their effects, and effects related to the agreement we entered into with the U.S. Administration in October 2026, on the pricing and sales of our products, manufacturing and the availability of raw materials; effectiveness of our optimization efforts; significant disruptions of information technology systems, including cybersecurity attacks, as well as risks and uncertainties related to the adoption of artificial intelligence technologies, and breaches of our data security; interruptions in our supply chain or problems with internal or third party manufacturing; challenges associated with conducting business globally, including political or economic instability, prolonged government shutdowns, widespread outbreaks of major diseases and major hostilities or acts of terrorism, such as the ongoing conflict in the Middle East and war involving Iran, and the international responses including economic, trade, financial or other restrictive measures directed specifically at Israel or Israeli companies, and the war between Russia and Ukraine; our ability to attract, hire, integrate and retain highly skilled personnel; our ability to successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and/or integrate acquisitions successfully and cost-effectively; and our prospects and opportunities for growth if we sell or plan to sell assets or business units and close or divest plants and facilities, as well as our ability to successfully and cost-effectively effectuate and consummate such sales and divestitures, including our planned divestiture of our API business;
compliance, regulatory and litigation matters, including: ongoing legal proceedings, legal settlements and loss contingencies, any failure to comply with complex legal and regulatory requirements, the effects of regulatory uncertainty and changes and the results of increased regulatory oversight, including expenditures required to ensure compliance with research, production and quality control regulations and remedial actions taken to address product issues, such as delayed product launches, product recalls, and facility shutdowns; the effects of governmental, regulatory and civil proceedings and litigation which we are, or in the future become, party to; the effects of reforms in healthcare regulation and related reductions in pharmaceutical pricing, reimbursement and coverage, including as a result of the One Big Beautiful Bill signed into law in the U.S. in July 2025 ("OBBBA"), which will likely reduce the number of insured in Medicaid and Health Insurance Exchange markets, potentially altering utilization patterns and shifting negotiating leverage among payors, our October 2026 agreement with the U.S. Administration referenced above, which followed U.S. Executive Orders issued in April and May 2025 intended to reduce the prices paid for prescription medicines, including Most-Favored-Nation pricing; legal and regulatory actions in connection with public concern over the abuse of opioid medications; our ability to timely make payments required under our nationwide opioids settlement agreement and provide our generic version of Narcan? (naloxone hydrochloride nasal spray) in the amounts and at the times required under the terms of such agreement; scrutiny from competition and pricing authorities around the world, including our ability to comply with and operate under our deferred prosecution agreement ("DPA") with the U.S. Department of Justice ("DOJ"); potential liability for intellectual property right infringement; significant product liability claims; claims brought by regulatory agencies; failure to comply with complex Medicare, Medicaid and other governmental programs' reporting and payment obligations; compliance with sanctions and trade control laws; environmental risks; and the impact of sustainability issues;
financial, economic and other risks, including: our exposure to currency fluctuations and restrictions as well as credit risks; impairments of our long-lived assets; potential significant increases in tax liabilities; the effect on our overall effective tax rate of the termination or expiration of governmental programs or tax benefits, or of a change in our business; the impact of any failure to maintain effective internal control over our financial reporting; our ability to successfully implement the process for terminating our ADS program and directly listing our ordinary shares in lieu of the ADSs (the "Conversion") and achieve our aims as a result of such Conversion, as further described in Part II, Item 5 our Quarterly Report on Form 10-Q and on our website at ir.tevapharm.com; and;

other factors discussed in this press release, in our Quarterly Report on Form 10-Q for the third quarter of 2026 and in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the sections captioned "Risk Factors" and "Cautionary Note Regarding Forward-Looking Statements." Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

Consolidated Statements of Income
(U.S. dollars in millions, except share and per share data)
(Unaudited)

			Three months ended				Nine months ended
			September 30,				September 30,
			2026		2025		2026		2025
Net revenues		$	4,395	$	4,480	$	12,519	$	12,547
Cost of sales			1,955		2,176		5,954		6,264
Gross profit			2,440		2,304		6,565		6,282
Research and development expenses			297		256		1,489		746
Selling and marketing expenses			709		656		2,122		1,933
General and administrative expenses			298		317		919		920
Intangible assets impairments			24		64		54		227
Other asset impairments, restructuring and other items			264		62		438		272
Legal settlements and loss contingencies			202		60		504		312
Other loss (income)			(68)		7		(96)		15
Operating income (loss)			714		882		1,135		1,857
Financial expenses, net			414		237		854		714
Income (loss) before income taxes			300		646		282		1,143
Income taxes (benefit)			66		214		254		210
Share in (profits) losses of associated companies, net			*		(2)		*		(4)
Net income (loss)			234		434		27		937
Net income (loss) attributable to redeemable and non-redeemable non-controlling interest			1		1		1		7
Net income (loss) attributable to Teva			233		433		26		930

Earnings (loss) per share attributable to Teva:	Basic	$	0.20	$	0.38	$	0.02	$	0.81
	Diluted	$	0.20	$	0.37	$	0.02	$	0.80
Weighted average number of shares (in millions):	Basic		1,166		1,147		1,162		1,144
	Diluted		1,183		1,164		1,180		1,160

Non-GAAP net income attributable to Teva for diluted earnings per share:**			1,013		910		1,655		2,281
Non-GAAP earnings per share attributable to Teva:**	Diluted	$	0.86	$	0.78	$	1.40	$	1.97

Non-GAAP average number of shares (in millions):	Diluted		1,183		1,164		1,180		1,160


Amounts may not add up due to rounding.

* Represents an amount less than $0.5 million.
** See reconciliation attached.

CONSOLIDATED BALANCE SHEETS
(U.S. dollars in millions, except for share data)
(Unaudited)

	September 30,		December 31,
	2026		2025
ASSETS
Current assets:
Cash and cash equivalents	$	4,085	$	3,556
Accounts receivables, net of allowance for credit losses of $71 million and $81 million as of September 30, 2026 and December 31, 2025, respectively.		3,837		3,709
Inventories		3,173		3,179
Prepaid expenses		1,014		1,122
Other current assets		658		539
Assets held for sale		1,836		1,842
Total current assets		14,602		13,946
Deferred income taxes		2,057		2,191
Other non-current assets		269		405
Property, plant and equipment, net		3,747		4,080
Operating lease right-of-use assets, net		321		345
Identifiable intangible assets, net		3,303		3,781
Goodwill		15,742		16,000
Total assets	$	40,042	$	40,748

LIABILITIES AND EQUITY
Current liabilities:
Short-term debt	$	4,038	$	1,820
Sales reserves and allowances		3,955		4,143
Accounts payables		2,551		2,531
Employee-related obligations		588		739
Accrued expenses		2,962		2,687
Other current liabilities		1,036		1,182
Liabilities held for sale		296		354
Total current liabilities		15,425		13,456

Long-term liabilities:
Deferred income taxes		263		296
Other taxes and long-term liabilities		3,422		3,808
Senior notes and loans		12,680		14,986
Operating lease liabilities		266		288
Total long-term liabilities		16,632		19,379

Equity:
Teva shareholders' equity:		7,979		7,910
Non-controlling interests		5		4
Total equity		7,984		7,914
Total liabilities and equity	$	40,042	$	40,748

Amounts may not add up due to rounding.

TEVA PHARMACEUTICAL INDUSTRIES LIMITED
CONSOLIDATED STATEMENTS OF CASH FLOWS
(U.S. dollars in millions)
(Unaudited)

	Three months ended			Nine months ended
	September 30,			September 30,
		2026	2025		2026	2025
Operating activities:
Net income (loss)	$	234	434	$	27	937
Adjustments to reconcile net income (loss) to net cash provided by operations:
Depreciation and amortization		245	249		725	742
Impairment of long-lived assets and assets held for sale		228	79		350	255
Acquired in-process research and development*		23	17		785	52
Net change in operating assets and liabilities		(682)	(578)		(1,523)	(1,647)
Deferred income taxes ? net and uncertain tax positions		53	107		56	(76)
Stock-based compensation		38	34		121	106
Loss on extinguishment of debt		224	-		224	-
Other items		(53)	27		(65)	122
Net loss (gain) from sale of business and long-lived assets		(69)	-		(89)	-
Net cash provided by (used in) operating activities		241	369		612	491

Investing activities:
Beneficial interest collected in exchange for securitized accounts receivables		327	274		992	932
Purchases of property, plant and equipment and intangible assets		(120)	(136)		(393)	(359)
Proceeds from sale of businesses and long-lived assets, net		47	8		93	34
Purchases of in-process research and development*		(46)	(12)		(747)	(41)
Other investing activities		2	1		3	6
Net cash provided by (used in) investing activities		210	135		(52)	572

Financing activities:
Repayment of senior notes and loans and other long-term liabilities		(4,883)	(444)		(4,906)	(4,112)
Proceeds from senior notes, net of issuance costs		4,845	(7)		4,845	2,298
Purchase of shares from redeemable and non-redeemable non-controlling interests		-	-		-	(38)
Dividends paid to redeemable and non-redeemable non-controlling interests		-	-		-	(340)
Other financing activities		43	(2)		78	1
Net cash provided by (used in) financing activities		6	(453)		18	(2,191)

Effect of exchange rate changes on cash and cash equivalents		(27)	(9)		(49)	31

Net change in cash and cash equivalents		430	42		529	(1,097)
Balance of cash and cash equivalents at beginning of period		3,655	2,161	$	3,556	3,300

Balance of cash and cash equivalents at end of period	$	4,085	2,203	$	4,085	2,203

Non-cash financing and investing activities:
Beneficial interest obtained in exchange for securitized accounts receivables	$	253	296	$	859	937
Receivable for sale of long-lived assets		90	-		90	-

* In the first nine months of 2026, mainly related to the acquisition of Emalex and its primary asset ecopipam (EBS-101).

Amounts may not add up due to rounding.
The accompanying notes are an integral part of the financial statements.

Reconciliation of net income (loss) attributable to Teva
to Non-GAAP net income (loss) attributable to Teva
(Unaudited)
			Three months ended			Nine months ended
			September 30,			September 30,
	($ in millions except per share amounts)		2026	2025		2026	2025
	Net income (Loss) attributable to Teva	$	233	433	$	26	930
	Increase (decrease) for excluded items:
	Amortization of purchased intangible assets		139	144		415	436
	Legal settlements and loss contingencies(1)		201	60		503	309
	Impairment of long-lived assets(2)		228	79		350	255
	Restructuring costs(3)		58	29		121	196
	Equity compensation		38	34		121	106
	Contingent consideration		2	16		25	46
	Financial expenses(4)		235	7		256	58
	Other non-GAAP items(5)		14	51		55	170
	Corresponding tax effects and unusual tax items(6)		(134)	58		(216)	(225)
	Non-GAAP net income attributable to Teva	$	1,013	910	$	1,655	2,281
	Non-GAAP tax rate(7)		16.5 %	14.7 %		22.1 %	16.0 %
	GAAP diluted earnings (loss) per share attributable to Teva	$	0.20	0.37	$	0.02	0.80
	EPS difference(8)		0.66	0.41		1.38	1.16
	Non-GAAP diluted EPS attributable to Teva(8)	$	0.86	0.78	$	1.40	1.97
	Non-GAAP average number of shares (in millions)(8)		1,183	1,164		1,180	1,160

(1)	For the three months ended September 30, 2026, adjustments for legal settlements and loss contingencies mainly consisted of (a) an update to the estimated provision recorded in connection with one of the Company's ongoing antitrust litigations in the amount of $133 million, and (b) an update to the estimated settlement provision for the opioid cases (mainly the effect of the passage of time on the net present value of the discounted payments) in the amount of $35 million. For the nine months ended September 30, 2026, adjustments for legal settlements and loss contingencies mainly consisted of (a) an estimated provision recorded in connection with one of the Company's ongoing antitrust litigations in the amount of $250 million, and (b) an update to the estimated settlement provision for the opioid cases (mainly the effect of the passage of time on the net present value of the discounted payments) in the amount of $132 million. For the three and nine months ended September 30, 2025, adjustments of legal settlements and loss contingencies mainly consisted of (a) an update to the estimated settlement provision for the opioid cases (mainly the effect of the passage of time on the net present value of the discounted payments) in the amount of $42 million and $139 million, respectively, and (b) an update to the estimated provision recorded for the claims brought by attorneys general representing states and territories throughout the U.S. in the generic drug antitrust litigation in the amount of $55 million.
(2)	The expense for the three and nine months ended September 30, 2026, mainly consisted of (a) impairment charges in connection with several manufacturing facilities in Europe in the amount of $140 million and $210 million, respectively, and (b) impairment charges in connection with the held for sale measurement of the API business (including its R&D, manufacturing and commercial activities), which includes an impact related to the expected gain from reclassification of currency translation adjustments in the amount of $49 million and $66 million, respectively. For the nine months ended September 30, 2025, the adjustment for impairment of long-lived assets was mainly related to intangible assets in the U.S. and Europe.
(3)	In the nine months ended September 30, 2026 and 2025, Teva recorded restructuring expenses of $121 million and $196 million, respectively, primarily related to optimization activities in connection with Teva's Transformation programs related to Teva's global organization and operations mainly through headcount reduction.
(4)	In the three and nine months ended September 30, 2026, Teva recorded $224 million of finance expenses related to a loss on extinguishment of debt.
(5)	Other non-GAAP items include other exceptional items that we believe are sufficiently large that their exclusion is important to facilitate an understanding of trends in our financial results, primarily related to material litigation fees, rationalization of our plants, accelerated depreciation and other unusual events.
(6)	Adjustments for corresponding tax effects and unusual tax items exclusively consisted of the tax impact directly attributable to the pre-tax items that are excluded from non-GAAP net income included in the other adjustments to this table.
(7)	Non-GAAP tax rate is tax expenses (benefit) excluding the impact of non-GAAP tax adjustments presented above as a percentage of income (loss) before income taxes excluding the impact of non-GAAP adjustments presented above. Our non-GAAP tax rate in the nine months ended September 30, 2026 was mainly affected by an unfavorable tax impact of a non-deductible acquired IPR&D charge related to the acquisition of Emalex and its primary asset ecopipam (EBS-101), the generation of profits in various jurisdictions in which tax rates are different than the Israeli tax rate, and other infrequent or non-recurring items, such as internal legal entities reorganization.
(8)	EPS difference and diluted non-GAAP EPS are calculated by dividing our non-GAAP net income attributable to Teva by our non-GAAP diluted weighted average number of shares.

Reconciliation of gross profit to Non-GAAP gross profit
(Unaudited)
		Three months ended			Nine months ended
		September 30,			September 30,
($ in millions)		2026	2025		2026	2025
Gross profit	$	2,440	2,304	$	6,565	6,282
Gross profit margin		55.5%	51.4%		52.4%	50.1%
Increase (decrease) for excluded items: (1)
Amortization of purchased intangible assets		129	134		387	406
Equity compensation		6	6		18	17
Other non-GAAP items		5	32		11	101
Non-GAAP gross profit	$	2,580	2,475	$	6,981	6,807
Non-GAAP gross profit margin (2)		58.7%	55.3%		55.8%	54.3%

(1) For further explanations, refer to the footnotes under the "Reconciliation of net income (loss) attributable to Teva to Non-GAAP net income (loss) attributable to Teva" table.
(2) Non-GAAP gross profit margin is non-GAAP gross profit as a percentage of revenue.

Reconciliation of operating income (loss) to Non-GAAP operating income (loss)
(Unaudited)

		Three months ended			Nine months ended
		September 30,			September 30,
($ in millions)		2026	2025		2026	2025
Operating income (loss)	$	714	882	$	1,135	1,857
Operating margin		16.2 %	19.7 %		9.1 %	14.8 %
Increase (decrease) for excluded items: (1)
Amortization of purchased intangible assets		139	144		415	436
Legal settlements and loss contingencies		201	60		503	309
Impairment of long-lived assets		228	79		350	255
Restructuring costs		58	29		121	196
Equity compensation		38	34		121	106
Contingent consideration		2	16		25	46
Loss (gain) on sale of business		(1)	6		(5)	19
Other non-GAAP items		15	45		60	149
Non-GAAP operating income (loss)	$	1,393	1,294	$	2,724	3,373
Non-GAAP operating margin(2)		31.7 %	28.9 %		21.8 %	26.9 %

(1) For further explanations, refer to the footnotes under the "Reconciliation of net income (loss) attributable to Teva to Non-GAAP net income (loss) attributable to Teva" table.
(2) Non-GAAP operating margin is Non-GAAP operating income as a percentage of revenues.

Reconciliation of net income (loss) to adjusted EBITDA
(Unaudited)
			Three months ended			Nine months ended
			September 30,			September 30,
($ in millions)			2026	2025		2026	2025
Net income (loss)		$	234	434	$	27	937
Increase (decrease) for excluded items:(1)
	Financial expenses		414	237		854	714
	Income taxes		66	214		254	210
	Share in profits (losses) of associated companies ?net		?	(2)		?	(4)
	Depreciation		106	105		311	306
	Amortization		139	144		415	436
EBITDA			959	1,131		1,861	2,599
	Legal settlements and loss contingencies		201	60		503	309
	Impairment of long lived assets		228	79		350	255
	Restructuring costs		58	29		121	196
	Equity compensation		38	34		121	106
	Contingent consideration		2	16		25	46
	Loss (Gain) on sale of Business		(1)	6		(5)	19
	Other non-GAAP items		12	40		50	137
Adjusted EBITDA		$	1,496	1,394	$	3,025	3,668

(1) For further explanations, refer to the footnotes under the "Reconciliation of net income (loss) attributable to Teva to Non-GAAP net income (loss) attributable to Teva" table.
? Represents an amount of less than $0.5 million.

Segment Information
(Unaudited)

	United States					Europe						International Markets
	Three months ended September 30,					Three months ended September 30,						Three months ended September 30,
	2026		2025			2026			2025			2026			2025

	(U.S. $ in millions)					(U.S. $ in millions)						(U.S. $ in millions)

Revenues	$	1,870		$	2,090		$	1,319		$	1,235		$	592		$	557
Cost of sales	467			645			562			570			276			280
Gross profit	1,403			1,446			757			665			316			278
R&D expenses	196			161			62			62			31			26
S&M expenses	306			248			211			225			125			122
G&A expenses	109			113			64			75			34			36
Other	?			(3)			?			?			?			?
Segment profit*	$	791		$	927		$	420		$	303		$	125		$	95

* Segment profit does not include amortization and certain other items.
? Represents an amount less than $0.5 million.

Segment Information
Unaudited

	United States				Europe				International Markets
	Nine months ended September 30,				Nine months ended September 30,				Nine months ended September 30,
	2026		2025		2026		2025		2026		2025

	(U.S. $ in millions)				(U.S. $ in millions)				(U.S. $ in millions)

Revenues	$	5,106	$	5,413	$	3,922	$	3,726	$	1,666	$	1,634
Cost of sales		1,462		1,742		1,727		1,687		823		835
Gross profit		3,644		3,670		2,195		2,039		843		799
R&D expenses		1,226		467		159		181		80		75
S&M expenses		898		741		648		652		370		353
G&A expenses		307		319		203		210		111		107
Other income		(9)		(1)		(3)		?		(8)		(3)
Segment profit	$	1,222	$	2,143	$	1,188	$	996	$	289	$	266

* Segment profit does not include amortization and certain other items.
? Represents an amount less than $0.5 million.

Reconciliation of our segment profit
to consolidated income (loss) before income taxes
	Three months ended
	September 30,
		2026		2025
	(U.S.$ in millions)

United States profit	$	791	$	927
Europe profit		420		303
International Markets profit		125		95
Total reportable segment profit		1,336		1,325
Profit (loss) of other activities		57		(31)
Amounts not allocated to segments:
Amortization		139		144
Other asset impairments, restructuring and other items		264		62
Intangible asset impairments		24		64
Legal settlements and loss contingencies		201		60
Other unallocated amounts		51		82
Consolidated operating income (loss)		714		882
Financial expenses - net		414		237
Consolidated income (loss) before income taxes	$	300	$	646

Reconciliation of our segment profit
to consolidated income (loss) before income taxes
	Nine months ended September 30,
	September 30,
	2026		2025
	(U.S.$ in millions)

United States profit	$	1,222	$	2,143
Europe profit		1,188		996
International Markets profit		289		266
Total reportable segment profit		2,699		3,405
Profit (loss) of other activities		25		(32)
Amounts not allocated to segments:
Amortization		415		436
Other asset impairments, restructuring and other items		438		272
Intangible asset impairments		54		227
Legal settlements and loss contingencies		503		309
Other unallocated amounts		179		272
Consolidated operating income (loss)		1,135		1,857
Financial expenses - net		854		714
Consolidated income (loss) before income taxes	$	282	$	1,143

Segment revenues by major products and activities
(Unaudited)

	Three months ended				Percentage
	September 30,				Change
	2026		2025		2026-2025
	(U.S.$ in millions)
United States segment
Generic products (including biosimilars)	$	718	$	1,175	(39)%
AJOVY		138		73	88 %
AUSTEDO		727		601	21 %
BENDEKA and TREANDA		30		35	(15)%
COPAXONE		58		62	(8)%
UZEDY		85		43	96 %
Other		114		101	13 %
Total		1,870		2,090	(11)%


	Three months ended				Percentage
	September 30,				Change
	2026		2025		2026-2025
	(U.S.$ in millions)
Europe segment
Generic products (including OTC and biosimilars)	$	1,033	$	982	5 %
AJOVY		84		66	28 %
COPAXONE		38		44	(12)%
Respiratory products		54		52	3 %
Other*		111		91	21 %
Total		1,319		1,235	7 %

*Other revenues in the third quarter of 2026 and 2025 include the sale of certain product rights

	Three months ended				Percentage
	September 30,				Change
	2026		2025		2026-2025
	(U.S.$ in millions)
International Markets segment
Generic products (including OTC and biosimilars)	$	407	$	421	(3)%
AJOVY		48		30	61 %
AUSTEDO		24		17	42 %
COPAXONE		8		8	8 %
Other*		105		82	28 %
Total		592		557	6 %

*Other revenues in the third quarter of 2026 and 2025 include the sale of certain product rights

Segment revenues by major products and activities
(Unaudited)

	Nine months ended
	September 30,				Percentage Change
	2026		2025		2025-2026
	(U.S.$ in millions)
United States segment
Generic products	$	1,990	$	2,984	(33)%
AJOVY		341		190	80 %
AUSTEDO		1,963		1,492	32 %
BENDEKA / TREANDA		85		111	(24)%
COPAXONE		182		179	2 %
UZEDY		225		136	65 %
Other		321		321	?
Total		5,106		5,413	(6)%

? Represents an amount less than 0.5%.

	Nine months ended
	September 30,				Percentage Change
	2026		2025		2025-2026
	(U.S.$ in millions)
Europe segment
Generic products	$	3,146	$	3,011	4 %
AJOVY		238		195	22 %
COPAXONE		127		135	(6)%
Respiratory products		171		162	6 %
Other*		241		223	8 %
Total		3,922		3,726	5 %

*Other revenues in the first nine months of 2026 and 2025 include the sale of certain product rights.

	Nine months ended
	September 30,				Percentage Change
	2026		2025		2025-2026
	(U.S.$ in millions)
International Markets segment
Generic products	$	1,212	$	1,298	(7)%
AJOVY		130		78	68 %
AUSTEDO		63		34	82 %
COPAXONE		22		25	(13)%
Other*		239		199	20 %
Total		1,666		1,634	2 %

*Other revenues in the first nine months of 2026 and 2025 include the sale of certain product rights.

Free cash flow reconciliation
(Unaudited)

		Three months ended September 30,
		2026		2025
	(U.S. $ in millions)

Net cash provided by (used in) operating activities		241		369
Beneficial interest collected in exchange for securitized account receivables		327		274
Capital investment		(120)		(136)
Proceeds from sale of businesses and long-lived assets, net		47		8
Free cash flow	$	495	$	515

Free cash flow reconciliation
(Unaudited)

	Nine months ended September 30,
	2026		2025

	(U.S. $ in millions)

Net cash provided by (used in) operating activities		612		491
Beneficial interest collected in exchange for securitized trade receivables		992		932
Capital investment		(393)		(359)
Proceeds from sale of businesses and long-lived assets, net		93		34
Free cash flow	$	1,305	$	1,098

Net debt reconciliation
unaudited

		September 30,
	2026
Short-term debt		4,038
Senior notes and loans		12,680
Total debt		16,718
Net of cash and cash equivalents		4,085
Net debt	$	12,633

Seyond Expands Smart City Solution with LiDAR-Powered Operational Twin Capabilities and Technology Collaborations

Tue, 03 Nov 2026 22:22:00 +0700

Combining comprehensive LiDAR sensing, agentic AI-powered analytics, and technology collaborations to advance smart cities, critical infrastructure and safe spaces.

SUNNYVALE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Seyond, a global provider of high-performance LiDAR solutions, is expanding its smart city and smart spaces solutions through advanced 3D sensing and technology collaborations.

By connecting spatial data with agentic AI-powered analytics and computing platforms, Seyond helps organizations improve safety, transportation, and infrastructure operations.

Growing Demand for Smart Cities and Intelligent Infrastructure

Smart cities are becoming an operational priority as organizations seek real-time intelligence to improve safety, transportation and operational efficiency. According to LP Information, the global smart-city LiDAR market was valued at approximately $358 million in 2025, with a projected compound annual growth rate of 18.7%, suggesting a market of approximately $425 million in 2026.

Demand for spatial intelligence now extends beyond roadways to airports, stadiums, utilities, data centers, and other critical infrastructures. These applications create opportunities to better understand movement, optimize space utilization, and improve operations.

Based on industry research and internal assumptions, Seyond estimates an illustrative annual serviceable addressable market of $1.3 billion to $2.0 billion in 2026 for expanded stationary LiDAR applications outside China. This sensor-focused estimate represents potential market opportunity, not projected company revenue.

Seyond: Enabling Spatial Intelligence Across Smart Environments

Seyond's comprehensive LiDAR portfolio, spanning ultra-long-range to short-range sensing, supports applications from transportation infrastructure to localized indoor and outdoor environments. Its technology generates high-resolution 3D spatial data to measure vehicle movement, pedestrian flows, and environmental activity without relying on identifiable photographic imagery, providing a privacy-conscious foundation for spatial analytics.

These capabilities support continuous spatial awareness across intersections, transportation hubs, commercial facilities, and public gathering spaces. Combined with AI-powered analytics and computing platforms, Seyond's sensing technology helps organizations translate physical-world data into actionable insights, enabling more responsive infrastructure and better-informed operational decisions.

Expanding Technology Collaborations to Deliver Complete Operational Twin Solutions

Delivering practical smart city solutions increasingly requires collaboration across sensing, computing, AI, and software. One example is the digital operational twins, dynamic digital representation of a physical environment that reflects activity and movement in real time, helping operators understand changing conditions and make informed decisions.

At Smart City Expo World Congress 2026, November 3-5 in Barcelona, Seyond will participate as an exhibition partner at the Dell Technologies booth, showcasing a live LiDAR-powered operational twin.

By combining Seyond's sensing capabilities with technologies from Dell and NVIDIA, the demonstration will illustrate how integrated solutions can support pedestrian-flow analysis, space utilization, and real-time operational awareness. The solution will feature a Dell Technologies system powered by the NVIDIA DGX Spark, which combines a 20-core Arm Grace CPU with an NVIDIA Blackwell GPU.

Fused data from LiDAR, video, and other sensors feeds a live operational twin, giving operators a unified view of activity across the environment. The solution integrates vision AI agents built with NVIDIA Metropolis Blueprint for video search and summarization (VSS) and NVIDIA Cosmos to enhance scene understanding and support informed operational decisions.

Seyond is also collaborating with AMSYS to advance integrated spatial intelligence solutions for large-scale venues and public environments. Combining Seyond's LiDAR sensing with the AMSYS Fusion Core Perception Platform, these solutions are designed to translate anonymous movement and occupancy data into actionable operational insights.

In a stadium or major event venue, for example, this approach could help operators monitor crowd density, analyze queues, and identify congestion across entrances and gathering areas. These insights could support better decisions about staffing, crowd movement, and resource allocation while maintaining a privacy-conscious approach to sensing.

Together, these collaborations demonstrate Seyond's expanding role in connecting advanced sensing with AI, computing, and operational software. As investment in intelligent infrastructure grows, Seyond remains focused on bringing practical spatial intelligence solutions to cities, critical infrastructure and safe spaces.

About Seyond

Seyond is a global provider of high-performance LiDAR solutions for automotive, robotics, intelligent transportation, smart infrastructure, and other applications. Its comprehensive portfolio of advanced 3D sensing technologies enables accurate, reliable spatial intelligence across a wide range of environments.

Hopscotch launches Hopscotch Public Engagement, a new entity dedicated to the European institutions

Tue, 03 Nov 2026 22:19:00 +0700

Press release

Paris, November 3rd 2026 --

Hopscotch launches Hopscotch Public Engagement, a new entity dedicated to the European institutions

The communications Group is combining its integrated expertise and international network to support the EU institutions meet their communication challenges and the demands of major public contracts.

HOPSCOTCH, the international communications Group founded in France, today announces the launch of Hopscotch Public Engagement. The new Brussels-based entity will primarily serve the EU institutions and, more broadly, the European public sector.

The launch reflects the Group's ambition to strengthen its presence with the EU institutions. Much of their communication work is commissioned through multi-year framework contracts spanning several areas of expertise and several countries. Hopscotch Public Engagement will meet these needs by drawing on the strengths of an integrated communications group: specialist expertise, sector knowledge and the ability to deliver across Europe.

An integrated offer built for the challenges of public communication

From 360? communication campaigns to events, digital, influence and public relations, Hopscotch Public Engagement brings together the Group's expertise to design and deliver communication strategies suited to the complexity of EU issues. This integrated approach meets the wide range of the institutions'needs. It is also built for framework contracts, which are typically split into multiple lots and require several disciplines and teams to work in close coordination.

The entity builds on the experience HOPSCOTCH has developed with private- and public-sector clients, adapting it to the conventions and requirements of EU institutional communication. This includes the Group's approaches to Relational Capital and augmented public relations, which help institutions explain their work, strengthen dialogue with their audiences and deliver their messages at the right time.

The offer relies on the Group's sector expertise and international network. As an independent European group, HOPSCOTCH has more than 40 offices worldwide. Its organisation is designed to support pan-European campaigns and to coordinate communication programmes across European markets.

The Group also draws on the experience of its international network, formerly Sopexa, in supporting regulated sectors and European programmes for agriculture and food industry players. It also runs international campaigns on behalf of the European Commission's Directorate-General for Agriculture and Rural Development (DG AGRI) and the European Research Executive Agency (REA).

"The launch of Hopscotch Public Engagement reflects a conviction the Group holds firmly: the biggest communication challenges now play out at European level. With this new entity, we are combining in-depth knowledge of the institutions with our network's ability to coordinate programmes across European and international markets," says Sylvain Rouchy, Vice President, Global Operations at HOPSCOTCH.

Based in Brussels, Hopscotch Public Engagement works alongside Hopscotch Belgium, the Group's brand communication agency for the Belgian market, led by M?lanie Rouchy.

"Setting up Hopscotch Public Engagement in Brussels is a great opportunity to strengthen synergies within the Group and to put our complementary expertise at the service of the European institutions," says M?lanie Rouchy, Managing Director of Hopscotch Belgium.

A shared ambition to serve Europe

Hopscotch Public Engagement is co-led by Caroline Danloy and Nicolas Balland. Between them, they bring knowledge of the European institutions, communications expertise and experience in leading multidisciplinary teams.

Caroline Danloy has extensive experience in strategic communication for international and European institutional clients. Over a 25-year career, she has served as Vice President at ICF Next, where she led 360? communication teams delivering major European campaigns.

"We are at a turning point for European democracy. Communicating about the work of the European institutions and the challenges they face is more important than ever, and it is a mission I have been proud to carry out for 25 years," says Caroline Danloy, Co-Managing Director of Hopscotch Public Engagement.

"Hopscotch brings a rare combination to this market: the scale and maturity of an international network headquartered in France, expertise spanning the public and private sectors, and real depth of subject knowledge. Communicating for public institutions involves many topics and stakeholders, and this combination is exactly what that complexity demands. Alongside Nicolas, whose experience I know well, I look forward to putting these strengths at the service of the European institutions with Hopscotch Public Engagement."

Nicolas Balland brings more than 20 years of experience in the communications industry, particularly in events, public relations and institutional communication. After holding various roles at ICF Next, he joined Tipik, where he led Event, Studio and Audiovisual teams before becoming Managing Director.

"This is a project Caroline and I had been thinking about for several years. When we met Hopscotch, we quickly realised that we shared the same ambition," explains Nicolas Balland, Co-Managing Director of Hopscotch Public Engagement.

"Today, we are proud to offer the European institutions the strength of a leading communications Group, combined with distinctive expertise and in-depth knowledge of European issues. Our ambition goes beyond designing and delivering communication campaigns: we want to build an organisation that connects institutions, citizens and ideas, and that takes concrete action for Europe."

About HOPSCOTCH

HOPSCOTCH is an international communications Group founded in France, driven by an entrepreneurial vision and the complementary nature of its talents and expertise.

HOPSCOTCH is a unique combination of expertise, driven by the belief that the value of a company or organisation lies in the quality of its Relational Capital.

With more than 1,200 employees, half of whom are based internationally (40 offices across 5 continents), HOPSCOTCH covers all areas of communication: influence, events, public relations, activations, digital, internal communication, public affairs, and marketing services.

HOPSCOTCH organises its agencies around its areas of expertise:

Event: Hopscotch Event, Hopscotch Congr?s, Hopscotch Moments, Sagarmatha.

Public Relations: Hopscotch PR, Le Public Syst?me PR, Human to Human, Hopscotch D?cideurs.

Digital and Marketing: heaven, AD Crew, Hopscotch Digital Studio, Sublime.

Media: Hopscotch Media

Sectorial expertise: Hopscotch Cin?ma, Hopscotch Luxe, Hopscotch Season, Hopscotch Sport, Hopscotch Tourism.

HOPSCOTCH has been committed to ambitious ecological and societal initiatives for over 15 years, validated by internationally recognized CSR certifications, including RSE Agences Actives, ISO 20121, and the EcoVadis Gold medal.

In 2026, HOPSCOTCH was named "Global Agency of the Year" by PRovoke Media.

Listed on Euronext Growth Paris (Ticker code: ALHOP FR ; ISIN code: FR 00000 6527 8), the Group represents a turnover of ?270,8 million and a gross margin of ?98,8 million in 2025.